锐哥来了 personal page - To The Moon

锐哥来了

锐哥来了

No personal profile

458Follow

6Followers

0Topic

0Badge

2021-09-17

?

Reminder: The Mid-Autumn Festival closure arrangement is here! Hong Kong stocks are closed on the 22nd

2021-09-17

?

Hong Kong domestic insurance stocks generally weakened, with Ping An of China falling more than 3%

2021-08-27

?

Sorry, the original content has been removed

2021-07-29

?

Forbes China Exclusive Interview with Xia Yu, Chairman of Kangfang Bio: Preference to Tiger Mountain Travel

2021-07-20

?

[Movement] Recovering today's lost ground, Wei Xiaoli stopped falling and rebounded

2021-07-20

?

Sorry, the original content has been removed

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3583528354923579","uuid":"3583528354923579","gmtCreate":1620537414910,"gmtModify":1630548055139,"name":"锐哥来了","pinyin":"rgllruigelaile","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/86eb4f1a6da7a549e0c096e4e1890a8e","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":6,"headSize":458,"tweetSize":244,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.93%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.41%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":884937555,"gmtCreate":1631845236277,"gmtModify":1676530650956,"author":{"id":"3583528354923579","authorId":"3583528354923579","name":"锐哥来了","avatar":"https://static.tigerbbs.com/86eb4f1a6da7a549e0c096e4e1890a8e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583528354923579","authorIdStr":"3583528354923579"},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/884937555","repostId":"1100031374","repostType":4,"repost":{"id":"1100031374","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631587259,"share":"https://ttm.financial/m/news/1100031374?lang=en_US&edition=fundamental","pubTime":"2021-09-14 10:40","market":"us","language":"zh","title":"Reminder: The Mid-Autumn Festival closure arrangement is here! Hong Kong stocks are closed on the 22nd","url":"https://stock-news.laohu8.com/highlight/detail?id=1100031374","media":"老虎资讯综合","summary":"2021年中秋节假期即将来临！各主要市场休市安排如下：港股：\n\n\n9月22日（周三）休市。9月23日（周四）起照常开市。\n\n\nA股：\n\n\n9月20日（周一）至9月21日（周二）休市。9月22日（周三）起照常开市。\n\n\n美股、英股、澳股、新加坡股市照常交易。\n\n\n沪股通和深股通：\n\n\n9月17日（周五）至9月22日（周三）关闭。9月23日（周四）起照常开通。\n\n\n港股通：\n\n\n9月16日（周四）至9月22日（周三）关闭。9月23日（周四）起照常开通。","content":"<p>The 2021 Mid-Autumn Festival holiday is upon us! The closure arrangements for each of the major markets are as follows:<img src=\"https://static.tigerbbs.com/a514042f0cc485274181ed3db4bcf541\" tg-width=\"1103\" tg-height=\"746\" width=\"100%\" height=\"auto\"><b>Hong Kong stocks:</b></p><p>Closed on Wednesday, September 22. The market will open as usual from September 23rd (Thursday).</p><p><b>A shares:</b></p><p>Closed from Monday, September 20th to Tuesday, September 21st. The market will open as usual from September 22nd (Wednesday).</p><p><b>US stocks, UK stocks, Australian stocks and Singapore stocks traded as usual.</b></p><p><b>Shanghai Stock Connect and Shenzhen Stock Connect:</b></p><p>Closed from Friday, September 17 to Wednesday, September 22. It will be open as usual from Thursday, September 23rd.</p><p><b>Hong Kong Stock Connect:</b></p><p>Closed Thursday, Sept. 16 through Wednesday, Sept. 22. It will be open as usual from Thursday, September 23rd.</p><p><img src=\"https://static.tigerbbs.com/75ca986d45037f1a0b113e295b82f3f9\" tg-width=\"2048\" tg-height=\"1311\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Reminder: The Mid-Autumn Festival closure arrangement is here! Hong Kong stocks are closed on the 22nd</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nReminder: The Mid-Autumn Festival closure arrangement is here! Hong Kong stocks are closed on the 22nd\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-09-14 10:40</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>The 2021 Mid-Autumn Festival holiday is upon us! The closure arrangements for each of the major markets are as follows:<img src=\"https://static.tigerbbs.com/a514042f0cc485274181ed3db4bcf541\" tg-width=\"1103\" tg-height=\"746\" width=\"100%\" height=\"auto\"><b>Hong Kong stocks:</b></p><p>Closed on Wednesday, September 22. The market will open as usual from September 23rd (Thursday).</p><p><b>A shares:</b></p><p>Closed from Monday, September 20th to Tuesday, September 21st. The market will open as usual from September 22nd (Wednesday).</p><p><b>US stocks, UK stocks, Australian stocks and Singapore stocks traded as usual.</b></p><p><b>Shanghai Stock Connect and Shenzhen Stock Connect:</b></p><p>Closed from Friday, September 17 to Wednesday, September 22. It will be open as usual from Thursday, September 23rd.</p><p><b>Hong Kong Stock Connect:</b></p><p>Closed Thursday, Sept. 16 through Wednesday, Sept. 22. It will be open as usual from Thursday, September 23rd.</p><p><img src=\"https://static.tigerbbs.com/75ca986d45037f1a0b113e295b82f3f9\" tg-width=\"2048\" tg-height=\"1311\" referrerpolicy=\"no-referrer\"></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/75ca986d45037f1a0b113e295b82f3f9","relate_stocks":{},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100031374","content_text":"2021年中秋节假期即将来临！各主要市场休市安排如下：港股：\n9月22日（周三）休市。9月23日（周四）起照常开市。\nA股：\n9月20日（周一）至9月21日（周二）休市。9月22日（周三）起照常开市。\n美股、英股、澳股、新加坡股市照常交易。\n沪股通和深股通：\n9月17日（周五）至9月22日（周三）关闭。9月23日（周四）起照常开通。\n港股通：\n9月16日（周四）至9月22日（周三）关闭。9月23日（周四）起照常开通。","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":4642,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":884998842,"gmtCreate":1631844289386,"gmtModify":1676530650623,"author":{"id":"3583528354923579","authorId":"3583528354923579","name":"锐哥来了","avatar":"https://static.tigerbbs.com/86eb4f1a6da7a549e0c096e4e1890a8e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583528354923579","authorIdStr":"3583528354923579"},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/884998842","repostId":"1115701930","repostType":4,"repost":{"id":"1115701930","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631842682,"share":"https://ttm.financial/m/news/1115701930?lang=en_US&edition=fundamental","pubTime":"2021-09-17 09:38","market":"other","language":"zh","title":"Hong Kong domestic insurance stocks generally weakened, with Ping An of China falling more than 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1115701930","media":"老虎资讯综合","summary":"9月17日讯，港股内险股普遍走弱，中国平安跌3.1%，中国人民保险集团跌2.5%，中国太保、中国太平跌超2%。","content":"<p><img src=\"https://static.tigerbbs.com/62fb8bf9e6b0319be20ba231a920a5d8\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\">On September 17th, insurance stocks in Hong Kong stocks generally weakened.<a href=\"https://laohu8.com/S/021318\">Ping An of China</a>down 3.1%,<a href=\"https://laohu8.com/S/01339\">The People's Insurance Company of China</a>down 2.5%,<a href=\"https://laohu8.com/S/601601\">China Pacific Insurance</a>、<a href=\"https://laohu8.com/S/00966\">China Taiping</a>It fell by more than 2%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong domestic insurance stocks generally weakened, with Ping An of China falling more than 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong domestic insurance stocks generally weakened, with Ping An of China falling more than 3%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-09-17 09:38</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><img src=\"https://static.tigerbbs.com/62fb8bf9e6b0319be20ba231a920a5d8\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\">On September 17th, insurance stocks in Hong Kong stocks generally weakened.<a href=\"https://laohu8.com/S/021318\">Ping An of China</a>down 3.1%,<a href=\"https://laohu8.com/S/01339\">The People's Insurance Company of China</a>down 2.5%,<a href=\"https://laohu8.com/S/601601\">China Pacific Insurance</a>、<a href=\"https://laohu8.com/S/00966\">China Taiping</a>It fell by more than 2%.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/082208e3c37780dd55878056410ffa43","relate_stocks":{"601318":"中国平安","02318":"中国平安","03145":"华夏亚洲高息股","LU":"陆金所"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1115701930","content_text":"9月17日讯，港股内险股普遍走弱，中国平安跌3.1%，中国人民保险集团跌2.5%，中国太保、中国太平跌超2%。","news_type":1,"symbols_score_info":{"601318":0.9,"03145":0.9,"LU":0.9,"02318":0.9}},"isVote":1,"tweetType":1,"viewCount":4303,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":819933613,"gmtCreate":1630026305032,"gmtModify":1676530202919,"author":{"id":"3583528354923579","authorId":"3583528354923579","name":"锐哥来了","avatar":"https://static.tigerbbs.com/86eb4f1a6da7a549e0c096e4e1890a8e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583528354923579","authorIdStr":"3583528354923579"},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/819933613","repostId":"1123728452","repostType":2,"isVote":1,"tweetType":1,"viewCount":3398,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":801885858,"gmtCreate":1627508922774,"gmtModify":1703491180130,"author":{"id":"3583528354923579","authorId":"3583528354923579","name":"锐哥来了","avatar":"https://static.tigerbbs.com/86eb4f1a6da7a549e0c096e4e1890a8e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583528354923579","authorIdStr":"3583528354923579"},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/801885858","repostId":"2154992231","repostType":2,"repost":{"id":"2154992231","kind":"news","pubTimestamp":1627378800,"share":"https://ttm.financial/m/news/2154992231?lang=en_US&edition=fundamental","pubTime":"2021-07-27 17:40","market":"hk","language":"zh","title":"Forbes China Exclusive Interview with Xia Yu, Chairman of Kangfang Bio: Preference to Tiger Mountain Travel","url":"https://stock-news.laohu8.com/highlight/detail?id=2154992231","media":"财经自媒体","summary":"　　康方生物有限公司创始人、董事长夏瑜向福布斯中国表示：“中国医药创新真正的崛起，必须依靠自身实力，培育创新氛围，打造创新体系，实现创新成果突破。从全球行业发展的商业模式来看，买买买的模式一点问题都没有，但像辉瑞、强生、阿斯利康、诺和诺德这类医药行业领军巨头企业，在国际上有一席之地的医药企业，中国要不要出现？”　　今年4月，康方生物公布了上市后的首份年度成绩单。","content":"<p><html><body><div><p cms-style=\"font-L\">Source: Forbes</p><p><p cms-style=\"font-L\">The track of pharmaceutical innovation,<a href=\"https://laohu8.com/S/PFE\">Pfizer</a>、<a href=\"https://laohu8.com/S/JNJ\">Johnson & Johnson</a>、<a href=\"https://laohu8.com/S/AZN\">AstraZeneca</a>、<a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>When there are many international giants, it may not be feasible to sharpen a sword in ten years.</p><p><p cms-style=\"font-L\">Xia Yu, founder and chairman of Kangfang Biological Co., Ltd., told Forbes China: \"<span><a href=\"https://laohu8.com/S/600056\">CHINA PHARMA</a></span><span></span>The real rise of innovation must rely on its own strength, cultivate an innovative atmosphere, build an innovative system, and achieve breakthroughs in innovative achievements. From the perspective of the business model of global industry development, there is no problem with the buy-buy-buy model at all, but leading giants in the pharmaceutical industry such as Pfizer, Johnson & Johnson, AstraZeneca, and Novo Nordisk, pharmaceutical companies with a place in the world, should China appear? \"</p><p><p cms-style=\"font-L\">\"China should emerge.\" Xia Yu was firm, and the R&D and innovation capabilities of these enterprises themselves are the key to becoming world-class leaders.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/324/w550h574/20210727/9053-eb59dd1acbf005315f9f014538a392da.jpg\"/><span></span></div></div><p cms-style=\"font-L\">Xia Yu, Founder and Chairman of Kangfang Biological Co., Ltd.</p><p><p cms-style=\"font-L align-right\">Credit: DR</p><p><p cms-style=\"font-L\">However, where should Chinese pharmaceutical companies that can compete with or even surpass giants place their hopes?</p><p><p cms-style=\"font-L\">In April this year, Kangfang Bio announced its first annual report card after listing. The announcement shows that by the end of 2020, Kangfang Bio's other income and gains exceeded 100 million yuan; R&D investment reached 764.5 million yuan.</p><p><p cms-style=\"font-L\">Ten years after its founding, Kangfang Bio has finally developed a pioneer track in the research and development of original antibody drugs in China: among more than 20 drugs under development, 6 bispecific antibodies with the world's first or leading progress, and a number of candidate drugs with the most cutting-edge targets. The research and development progress is leading in the world, with more than 20 clinical research projects in clinical phase II and later stages, and the core world's first double antibody is about to be listed... A Chinese biotechnology company that has actually gone abroad through self-research and development has quietly risen.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/80/w550h330/20210727/0264-3242e677075ee7bd62b8859c7068fc7c.jpg\"/><span></span></div></div><p cms-style=\"font-L\">The world's first double antibody cadonilimab</p><p><p cms-style=\"font-L align-right\">Credit: DR</p><p><p cms-style=\"font-L\">　　<font cms-style=\"font-L strong-Bold\">Buy, buy, buy mode, can't buy China's Pfizer, China's Johnson & Johnson</font></p><p><p cms-style=\"font-L\">More than a decade ago, Xia Yu, who had struggled to make a comfortable and superior life in a foreign country, returned to China, and the idea of starting a business emerged among the bustling crowds in Beijing. As a Chinese, Xia Yu's first question is, does China need original new drugs? Can the Chinese only use foreign outdated medicines from ten years ago for decades?</p><p><p cms-style=\"font-L\">\"In fact, if I do the same thing (pharmaceutical R&D) in the United States, I will likely not do it at a certain stage of R&D.\" Xia Yu further said: \"Because I know very well that the investment in production and commercialization and even clinical trials after R&D is too huge. But today, with the development of the domestic pharmaceutical industry, whether from the perspective of capital market development or industrial policy support, China actually has the possibility to capture the global industry highland.\"</p><p><p cms-style=\"font-L\">Of course, for Chinese pharmaceutical companies, a natural shortcoming in participating in global competition is that they started late and the overall development level of the industry is relatively backward. \"But a gap doesn't mean that we can't lead the world in certain fields, certain directions and certain stages.\"</p><p><p cms-style=\"font-L\">Xia Yu knows very well that there are two ways to choose from when entering the pharmaceutical industry to start a business. One way is original R&D, using the company's own internal R&D strength to obtain competitive innovative drugs; Another way is to improve the company's R&D pipeline through external introduction.</p><p><p cms-style=\"font-L\">Ten years ago, the research and development of new drugs in China's pharmaceutical industry at that time could be described as \"poor and white\". Xia Yu still chose the original road.</p><p><p cms-style=\"font-L\">Even in recent years, with the return of a group of returned entrepreneurs, it has actually driven the return of individual advanced technologies. However, Xia Yu has been thinking and practicing how to drive the overall pharmaceutical industry to deeply cultivate and build in China, and how to establish a truly advanced R&D system in China. Without rushing for a while, or even sacrificing the opportunity to produce advanced products, Xia Yu led Kangfang Bio to invest a lot of energy in creating an integrated R&D system internally at the beginning of its establishment.</p><p><p cms-style=\"font-L\">Only under such an innovative R&D system, with this willingness and ideal to grow, and from the source of R&D to industrialization, will China's Pfizer and China's Johnson & Johnson appear in the future.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/40/w550h290/20210727/55da-1b43fa5d55b5db075d491294cb78bfd6.png\"/><span></span></div></div><p cms-style=\"font-L\">Exterior view of Kangfang Biotech Guangzhou Base</p><p><p cms-style=\"font-L align-right\">Credit: DR</p><p><p cms-style=\"font-L\">Since its establishment in 2012, Kangfang Bio has started from the highest-end source scientific research and innovation, until the layout of production, commercialization and clinical industrial stages, focusing on the development of the world's most cutting-edge tumor immunotherapy antibodies. At present, Kangfang Bio has developed more than 20 innovative drug candidates, of which 13 innovative antibody new drugs are in the clinical research stage.</p><p><p cms-style=\"font-L\">\"In fact, not making original new drugs is an understandable business model. The only thing I think is wrong is that this thing has become a Red Sea, and anything that goes into the Red Sea will be terrible.\" In China, an industrial reality faced by drug supervision is that even by 2016, the total R&D investment of pharmaceutical companies nationwide is still less than that of the world's largest pharmaceutical companies.</p><p><p cms-style=\"font-L\">\"On the one hand, it is necessary to form a soil for cultivating industrial development, and on the other hand, it is necessary to establish a competitive mechanism for the survival of the fittest. The current pharmaceutical giants in the United States are also the result of the survival of the fittest after experiencing industrial development and market competition. In China, such a scene will also appear in the future.\" Xia Yu said.</p><p><p cms-style=\"font-L\">　　<font cms-style=\"font-L strong-Bold\">The two heavens of ice and fire, the double-edged sword of capital</font></p><p><p cms-style=\"font-L\">Even in the past two years, with the reform of the new stock listing system of the Hong Kong Stock Exchange and the introduction of the registration system of the Science and Technology Innovation Board, new financing opportunities and more diversified choices have been provided for pharmaceutical companies with different markets, different investor compositions and different entry and exit mechanisms. What remains unchanged is that the business model of entrepreneurship must be able to stand the test of capital preservation and appreciation ability.</p><p><p cms-style=\"font-L\">Xia Yu recalled that in the early days of starting a business, if we really didn't get the financial support of the capital market at that time, we might have survived in other ways, but what is certain is that it is far from possible to achieve the current rapid development. In fact, a great role of capital is to help accelerate the development of enterprises, so that enterprises can focus more on building senior innovation competitiveness in a competitive environment. \"</p><p><p cms-style=\"font-L\">　　<a href=\"https://laohu8.com/S/V03.SI\">Startups</a>The business model chosen at each stage of development will have different embodiments at different stages of development.</p><p><p cms-style=\"font-L\">At the beginning of the business in 2012, drug innovation companies were not as sought after in the capital market as they are now. In order to survive and continue to develop, at the end of 2015, Xia Yu decided to license an innovative product of Kangfang Bio to the giant<a href=\"https://laohu8.com/S/MRK\">Merck</a>。 \"I think from the perspective of business model, at that moment, it must be a decision conducive to the long-term development of the company, which supports our long-term development.\" On the other hand, this is China's first innovative antibody drug independently developed by a local company to be licensed to the international TOP5 pharmaceutical giant, and it has also become one of the landmark events that China's innovative drug industry has truly gone global and been recognized internationally. It has also allowed Kangfang Bio to enter the world stage of drug innovation for the first time.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/117/w550h367/20210727/b886-3bb61d586babf8c3cb5f2b87668503b0.jpg\"/><span></span></div></div><p cms-style=\"font-L\">Production workshop</p><p><p cms-style=\"font-L align-right\">Credit: DR</p><p><p cms-style=\"font-L\">\"Actually, I understand the capital market very well. In the early stage of starting the business, we spent a lot of time developing the platform, so we have gained a lot of results on the platform now. Nowadays, Kangfang, while efficiently promoting the clinical development of the existing pipeline, we will focus more on the world's cutting-edge target drugs in product development. Because we already have a good product foundation and development experience, we have also been recognized by investors. But if I take investors' money to do 10 years of innovative research and development without any products, which investor can agree? \"</p><p><p cms-style=\"font-L\">If the birth of a new drug is a relay race for various companies in the industrial chain, Xia Yu is determined to do a marathon.</p><p><p cms-style=\"font-L\">　　<font cms-style=\"font-L strong-Bold\">From studying overseas alone to returning home to start a business with a market value of 50 billion</font></p><p><p cms-style=\"font-L\">A phenomenon of concern is that nearly 20% of the founders of innovative companies emerging in the pharmaceutical industry are women. Having accumulated senior experience in biological drug research and development, as an expert in antibody drug research and development, Xia Yu decided to return to China to start a business, and founded Kangfang Bio with three other returnees. Xia Yu, as the chairman, is the only woman in the management team.</p><p><p cms-style=\"font-L\">Xia Yu said: \"Women are more tolerant, women are more resilient, and they are persistent and persistent in one thing.\"</p><p><p cms-style=\"font-L\">\"But any perfection is relative, and there is no perfect person for entrepreneurship.\"</p><p><p cms-style=\"font-L\">Just like Xia Yu initially decided to return to China to start a business, even with the support of her daughter's family, she still had to face the confusion around her. As a mother, shouldn't she be fully accompanied by her daughter during the critical stage of her growth? As a woman, why do you have to toss the so-called career again in a comfortable middle age?</p><p><p cms-style=\"font-L\">With the sting of not being understood, Xia Yu and her daughter transformed and grew up together. Nowadays, my daughter said, her mother is the person she admires the most.</p><p><p cms-style=\"font-L\">At this time, it has been more than ten years since Xia Yu founded Kangfang Bio alone.</p><p><p cms-style=\"font-L\">Following the official listing of Kangfang Bio on the Hong Kong Stock Exchange in 2020, the total market value once hit HK$55 billion.</p><p><p cms-style=\"font-L\">Looking back at his youth, Xia Yu, who was born as a master, said, \"I went abroad as soon as I graduated from college. At that time, I got a scholarship completely by myself, and I ran abroad without a few dollars. When I went abroad, it was really different from China. At that time, I was very nervous, and I didn't know what would happen next.\"</p><p><p cms-style=\"font-L\">In the next 20 years, Xia Yu worked in Sino-US Crown Biotech,<a href=\"https://laohu8.com/S/PDLI\">PDL BioPharma</a>He held management positions in multinational pharmaceutical companies such as Bayer and CrownBio in Germany, and conducted scientific research at the University of Louisville School of Medicine in the United States after completing postdoctoral research at the University of Glasgow in the United Kingdom; Played a decisive role in developing and executing strategies for the company and establishing a joint venture with Pfizer during his tenure as Senior Vice President of Mid-US Corontech Biotechnology.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/462/w550h712/20210727/7570-3cd7c1d54dc532007a1a67b35d002611.jpg\"/><span></span></div></div><p cms-style=\"font-L\">Dr. Xia Yu</p><p><p cms-style=\"font-L align-right\">Credit: DR</p><p><p cms-style=\"font-L\">Within the founding team, Xia Yu is responsible for the overall strategic planning, business and scientific development direction of the company. Xia Yu said, \"At the moment of choice of enterprise development, what is needed is the courage to make a decision and bear the pressure and responsibility of decision-making. It does test the leader's foresight and control of enterprise development.\"</p><p><p cms-style=\"font-L\">After the fruitful results of the \"original R&D route\" campaign, Xia Yu now leads the next challenge that Kangfang Bio will face: product commercialization, from biotech to biopharma.</p><p><p cms-style=\"font-L\">In Xia Yu's view, \"Some companies may have made it very clear from the beginning of their business that they don't involve production or future commercialization, so they do what they are good at. This is also a good business model. But there are some companies, such as Kangfang Bio, in fact, I don't set limits for the future. As long as conditions allow and in line with the company's development strategy, we will push forward.</p><p><p cms-style=\"font-L\">The first condition, for example, I have enough talents and abilities to do both production and commercialization, which requires a larger enterprise development goal to promote. In addition, as a founder, I also want to have this ideal, which I think is very important. Because the more we achieve this stage of production and commercialization, the more uncontrollable it is in a sense, and courage is necessary. \"</p><p><p cms-style=\"font-L\">Knowing that there are tigers in the mountains, they prefer to go to the tiger This is Xia Yu's persistence and tenacity.</p><p><div><div><img src=\"\"/></div><div>Massive information, accurate interpretation, all in<a href=\"https://laohu8.com/S/SINA\">SINA</a>Finance APP</div></div>Editor in charge: Liu Wanli SF014</p><p></div></body></html></p>","source":"sina","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Forbes China Exclusive Interview with Xia Yu, Chairman of Kangfang Bio: Preference to Tiger Mountain Travel</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForbes China Exclusive Interview with Xia Yu, Chairman of Kangfang Bio: Preference to Tiger Mountain Travel\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">财经自媒体</strong><span class=\"h-time small\">2021-07-27 17:40</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><body><div><p cms-style=\"font-L\">Source: Forbes</p><p><p cms-style=\"font-L\">The track of pharmaceutical innovation,<a href=\"https://laohu8.com/S/PFE\">Pfizer</a>、<a href=\"https://laohu8.com/S/JNJ\">Johnson & Johnson</a>、<a href=\"https://laohu8.com/S/AZN\">AstraZeneca</a>、<a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>When there are many international giants, it may not be feasible to sharpen a sword in ten years.</p><p><p cms-style=\"font-L\">Xia Yu, founder and chairman of Kangfang Biological Co., Ltd., told Forbes China: \"<span><a href=\"https://laohu8.com/S/600056\">CHINA PHARMA</a></span><span></span>The real rise of innovation must rely on its own strength, cultivate an innovative atmosphere, build an innovative system, and achieve breakthroughs in innovative achievements. From the perspective of the business model of global industry development, there is no problem with the buy-buy-buy model at all, but leading giants in the pharmaceutical industry such as Pfizer, Johnson & Johnson, AstraZeneca, and Novo Nordisk, pharmaceutical companies with a place in the world, should China appear? \"</p><p><p cms-style=\"font-L\">\"China should emerge.\" Xia Yu was firm, and the R&D and innovation capabilities of these enterprises themselves are the key to becoming world-class leaders.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/324/w550h574/20210727/9053-eb59dd1acbf005315f9f014538a392da.jpg\"/><span></span></div></div><p cms-style=\"font-L\">Xia Yu, Founder and Chairman of Kangfang Biological Co., Ltd.</p><p><p cms-style=\"font-L align-right\">Credit: DR</p><p><p cms-style=\"font-L\">However, where should Chinese pharmaceutical companies that can compete with or even surpass giants place their hopes?</p><p><p cms-style=\"font-L\">In April this year, Kangfang Bio announced its first annual report card after listing. The announcement shows that by the end of 2020, Kangfang Bio's other income and gains exceeded 100 million yuan; R&D investment reached 764.5 million yuan.</p><p><p cms-style=\"font-L\">Ten years after its founding, Kangfang Bio has finally developed a pioneer track in the research and development of original antibody drugs in China: among more than 20 drugs under development, 6 bispecific antibodies with the world's first or leading progress, and a number of candidate drugs with the most cutting-edge targets. The research and development progress is leading in the world, with more than 20 clinical research projects in clinical phase II and later stages, and the core world's first double antibody is about to be listed... A Chinese biotechnology company that has actually gone abroad through self-research and development has quietly risen.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/80/w550h330/20210727/0264-3242e677075ee7bd62b8859c7068fc7c.jpg\"/><span></span></div></div><p cms-style=\"font-L\">The world's first double antibody cadonilimab</p><p><p cms-style=\"font-L align-right\">Credit: DR</p><p><p cms-style=\"font-L\">　　<font cms-style=\"font-L strong-Bold\">Buy, buy, buy mode, can't buy China's Pfizer, China's Johnson & Johnson</font></p><p><p cms-style=\"font-L\">More than a decade ago, Xia Yu, who had struggled to make a comfortable and superior life in a foreign country, returned to China, and the idea of starting a business emerged among the bustling crowds in Beijing. As a Chinese, Xia Yu's first question is, does China need original new drugs? Can the Chinese only use foreign outdated medicines from ten years ago for decades?</p><p><p cms-style=\"font-L\">\"In fact, if I do the same thing (pharmaceutical R&D) in the United States, I will likely not do it at a certain stage of R&D.\" Xia Yu further said: \"Because I know very well that the investment in production and commercialization and even clinical trials after R&D is too huge. But today, with the development of the domestic pharmaceutical industry, whether from the perspective of capital market development or industrial policy support, China actually has the possibility to capture the global industry highland.\"</p><p><p cms-style=\"font-L\">Of course, for Chinese pharmaceutical companies, a natural shortcoming in participating in global competition is that they started late and the overall development level of the industry is relatively backward. \"But a gap doesn't mean that we can't lead the world in certain fields, certain directions and certain stages.\"</p><p><p cms-style=\"font-L\">Xia Yu knows very well that there are two ways to choose from when entering the pharmaceutical industry to start a business. One way is original R&D, using the company's own internal R&D strength to obtain competitive innovative drugs; Another way is to improve the company's R&D pipeline through external introduction.</p><p><p cms-style=\"font-L\">Ten years ago, the research and development of new drugs in China's pharmaceutical industry at that time could be described as \"poor and white\". Xia Yu still chose the original road.</p><p><p cms-style=\"font-L\">Even in recent years, with the return of a group of returned entrepreneurs, it has actually driven the return of individual advanced technologies. However, Xia Yu has been thinking and practicing how to drive the overall pharmaceutical industry to deeply cultivate and build in China, and how to establish a truly advanced R&D system in China. Without rushing for a while, or even sacrificing the opportunity to produce advanced products, Xia Yu led Kangfang Bio to invest a lot of energy in creating an integrated R&D system internally at the beginning of its establishment.</p><p><p cms-style=\"font-L\">Only under such an innovative R&D system, with this willingness and ideal to grow, and from the source of R&D to industrialization, will China's Pfizer and China's Johnson & Johnson appear in the future.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/40/w550h290/20210727/55da-1b43fa5d55b5db075d491294cb78bfd6.png\"/><span></span></div></div><p cms-style=\"font-L\">Exterior view of Kangfang Biotech Guangzhou Base</p><p><p cms-style=\"font-L align-right\">Credit: DR</p><p><p cms-style=\"font-L\">Since its establishment in 2012, Kangfang Bio has started from the highest-end source scientific research and innovation, until the layout of production, commercialization and clinical industrial stages, focusing on the development of the world's most cutting-edge tumor immunotherapy antibodies. At present, Kangfang Bio has developed more than 20 innovative drug candidates, of which 13 innovative antibody new drugs are in the clinical research stage.</p><p><p cms-style=\"font-L\">\"In fact, not making original new drugs is an understandable business model. The only thing I think is wrong is that this thing has become a Red Sea, and anything that goes into the Red Sea will be terrible.\" In China, an industrial reality faced by drug supervision is that even by 2016, the total R&D investment of pharmaceutical companies nationwide is still less than that of the world's largest pharmaceutical companies.</p><p><p cms-style=\"font-L\">\"On the one hand, it is necessary to form a soil for cultivating industrial development, and on the other hand, it is necessary to establish a competitive mechanism for the survival of the fittest. The current pharmaceutical giants in the United States are also the result of the survival of the fittest after experiencing industrial development and market competition. In China, such a scene will also appear in the future.\" Xia Yu said.</p><p><p cms-style=\"font-L\">　　<font cms-style=\"font-L strong-Bold\">The two heavens of ice and fire, the double-edged sword of capital</font></p><p><p cms-style=\"font-L\">Even in the past two years, with the reform of the new stock listing system of the Hong Kong Stock Exchange and the introduction of the registration system of the Science and Technology Innovation Board, new financing opportunities and more diversified choices have been provided for pharmaceutical companies with different markets, different investor compositions and different entry and exit mechanisms. What remains unchanged is that the business model of entrepreneurship must be able to stand the test of capital preservation and appreciation ability.</p><p><p cms-style=\"font-L\">Xia Yu recalled that in the early days of starting a business, if we really didn't get the financial support of the capital market at that time, we might have survived in other ways, but what is certain is that it is far from possible to achieve the current rapid development. In fact, a great role of capital is to help accelerate the development of enterprises, so that enterprises can focus more on building senior innovation competitiveness in a competitive environment. \"</p><p><p cms-style=\"font-L\">　　<a href=\"https://laohu8.com/S/V03.SI\">Startups</a>The business model chosen at each stage of development will have different embodiments at different stages of development.</p><p><p cms-style=\"font-L\">At the beginning of the business in 2012, drug innovation companies were not as sought after in the capital market as they are now. In order to survive and continue to develop, at the end of 2015, Xia Yu decided to license an innovative product of Kangfang Bio to the giant<a href=\"https://laohu8.com/S/MRK\">Merck</a>。 \"I think from the perspective of business model, at that moment, it must be a decision conducive to the long-term development of the company, which supports our long-term development.\" On the other hand, this is China's first innovative antibody drug independently developed by a local company to be licensed to the international TOP5 pharmaceutical giant, and it has also become one of the landmark events that China's innovative drug industry has truly gone global and been recognized internationally. It has also allowed Kangfang Bio to enter the world stage of drug innovation for the first time.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/117/w550h367/20210727/b886-3bb61d586babf8c3cb5f2b87668503b0.jpg\"/><span></span></div></div><p cms-style=\"font-L\">Production workshop</p><p><p cms-style=\"font-L align-right\">Credit: DR</p><p><p cms-style=\"font-L\">\"Actually, I understand the capital market very well. In the early stage of starting the business, we spent a lot of time developing the platform, so we have gained a lot of results on the platform now. Nowadays, Kangfang, while efficiently promoting the clinical development of the existing pipeline, we will focus more on the world's cutting-edge target drugs in product development. Because we already have a good product foundation and development experience, we have also been recognized by investors. But if I take investors' money to do 10 years of innovative research and development without any products, which investor can agree? \"</p><p><p cms-style=\"font-L\">If the birth of a new drug is a relay race for various companies in the industrial chain, Xia Yu is determined to do a marathon.</p><p><p cms-style=\"font-L\">　　<font cms-style=\"font-L strong-Bold\">From studying overseas alone to returning home to start a business with a market value of 50 billion</font></p><p><p cms-style=\"font-L\">A phenomenon of concern is that nearly 20% of the founders of innovative companies emerging in the pharmaceutical industry are women. Having accumulated senior experience in biological drug research and development, as an expert in antibody drug research and development, Xia Yu decided to return to China to start a business, and founded Kangfang Bio with three other returnees. Xia Yu, as the chairman, is the only woman in the management team.</p><p><p cms-style=\"font-L\">Xia Yu said: \"Women are more tolerant, women are more resilient, and they are persistent and persistent in one thing.\"</p><p><p cms-style=\"font-L\">\"But any perfection is relative, and there is no perfect person for entrepreneurship.\"</p><p><p cms-style=\"font-L\">Just like Xia Yu initially decided to return to China to start a business, even with the support of her daughter's family, she still had to face the confusion around her. As a mother, shouldn't she be fully accompanied by her daughter during the critical stage of her growth? As a woman, why do you have to toss the so-called career again in a comfortable middle age?</p><p><p cms-style=\"font-L\">With the sting of not being understood, Xia Yu and her daughter transformed and grew up together. Nowadays, my daughter said, her mother is the person she admires the most.</p><p><p cms-style=\"font-L\">At this time, it has been more than ten years since Xia Yu founded Kangfang Bio alone.</p><p><p cms-style=\"font-L\">Following the official listing of Kangfang Bio on the Hong Kong Stock Exchange in 2020, the total market value once hit HK$55 billion.</p><p><p cms-style=\"font-L\">Looking back at his youth, Xia Yu, who was born as a master, said, \"I went abroad as soon as I graduated from college. At that time, I got a scholarship completely by myself, and I ran abroad without a few dollars. When I went abroad, it was really different from China. At that time, I was very nervous, and I didn't know what would happen next.\"</p><p><p cms-style=\"font-L\">In the next 20 years, Xia Yu worked in Sino-US Crown Biotech,<a href=\"https://laohu8.com/S/PDLI\">PDL BioPharma</a>He held management positions in multinational pharmaceutical companies such as Bayer and CrownBio in Germany, and conducted scientific research at the University of Louisville School of Medicine in the United States after completing postdoctoral research at the University of Glasgow in the United Kingdom; Played a decisive role in developing and executing strategies for the company and establishing a joint venture with Pfizer during his tenure as Senior Vice President of Mid-US Corontech Biotechnology.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/462/w550h712/20210727/7570-3cd7c1d54dc532007a1a67b35d002611.jpg\"/><span></span></div></div><p cms-style=\"font-L\">Dr. Xia Yu</p><p><p cms-style=\"font-L align-right\">Credit: DR</p><p><p cms-style=\"font-L\">Within the founding team, Xia Yu is responsible for the overall strategic planning, business and scientific development direction of the company. Xia Yu said, \"At the moment of choice of enterprise development, what is needed is the courage to make a decision and bear the pressure and responsibility of decision-making. It does test the leader's foresight and control of enterprise development.\"</p><p><p cms-style=\"font-L\">After the fruitful results of the \"original R&D route\" campaign, Xia Yu now leads the next challenge that Kangfang Bio will face: product commercialization, from biotech to biopharma.</p><p><p cms-style=\"font-L\">In Xia Yu's view, \"Some companies may have made it very clear from the beginning of their business that they don't involve production or future commercialization, so they do what they are good at. This is also a good business model. But there are some companies, such as Kangfang Bio, in fact, I don't set limits for the future. As long as conditions allow and in line with the company's development strategy, we will push forward.</p><p><p cms-style=\"font-L\">The first condition, for example, I have enough talents and abilities to do both production and commercialization, which requires a larger enterprise development goal to promote. In addition, as a founder, I also want to have this ideal, which I think is very important. Because the more we achieve this stage of production and commercialization, the more uncontrollable it is in a sense, and courage is necessary. \"</p><p><p cms-style=\"font-L\">Knowing that there are tigers in the mountains, they prefer to go to the tiger This is Xia Yu's persistence and tenacity.</p><p><div><div><img src=\"\"/></div><div>Massive information, accurate interpretation, all in<a href=\"https://laohu8.com/S/SINA\">SINA</a>Finance APP</div></div>Editor in charge: Liu Wanli SF014</p><p></div></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"https://finance.sina.com.cn/chanjing/cyxw/2021-07-27/doc-ikqcfnca9352486.shtml\">财经自媒体</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/bc7ad619aa7e42a7db4703997b65806b","relate_stocks":{"09926":"康方生物"},"source_url":"https://finance.sina.com.cn/chanjing/cyxw/2021-07-27/doc-ikqcfnca9352486.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","article_id":"2154992231","content_text":"来源：福布斯\n　　医药创新这个赛道，辉瑞、强生、阿斯利康、诺和诺德等国际巨头林立，十年磨一剑也未必可行。\n　　康方生物有限公司创始人、董事长夏瑜向福布斯中国表示：“中国医药创新真正的崛起，必须依靠自身实力，培育创新氛围，打造创新体系，实现创新成果突破。从全球行业发展的商业模式来看，买买买的模式一点问题都没有，但像辉瑞、强生、阿斯利康、诺和诺德这类医药行业领军巨头企业，在国际上有一席之地的医药企业，中国要不要出现？”\n　　“中国应该出现。”夏瑜很坚定，而这些企业自身的研发创新能力是企业成为世界级领导者的关键。\n\n\n\n　　康方生物有限公司创始人、董事长夏瑜\n　　图片来源：DR\n　　只是，能与巨头比肩甚至超越巨头的中国医药企业，应该把希望寄托于哪里？\n　　今年4月，康方生物公布了上市后的首份年度成绩单。公告显示，截至2020年底，康方生物其他收入及收益超1亿元；研发投入达到7.645亿元。\n　　创业十年，康方生物终于开拓出一条中国原创抗体药物研发的先行者赛道：20多款在研药物中，6款全球首创或进度领先的双特异性抗体，多款最前沿靶点候选药物研发进度全球领先，超过20个临床研究项目在临床II期及往后阶段，核心全球首创双抗即将上市……一家实打实通过自我研发走出国门的中国生物科技公司悄然崛起。\n\n\n\n　　全球首创双抗cadonilimab\n　　图片来源：DR\n　　买买买模式，买不来中国的辉瑞、中国的强生\n　　十几年前，在异国他乡已打拼出安逸优越生活的夏瑜回国，在北京熙熙攘攘的人群中，冒出创业的念头。作为一名中国人，夏瑜首先想到的问题是，中国是不是需要原创新药？中国人难道只能数十年如一日地用国外十年前的过时药？\n　　“其实，如果我在美国做同样的事情（医药研发），我很有可能做到一个研发某个阶段就不做了。”夏瑜进一步表示：“因为我自己也很清楚，研发后的生产和商业化，甚至临床实验的投入实在太巨大了。但时至今日，随着国内医药行业的发展，无论是从资本市场发展还是产业政策的支持来看，中国其实已经拥有了去攻占全球行业高地的可能。”\n　　当然，参与全球竞争，对于中国医药企业来说，一个天然短板是起步晚、行业整体发展水平相对落后。“但有差距并不代表我们自己在某一些领域、某一些方向、某一些阶段上，就没有办法做到世界领先。”\n　　夏瑜很清楚，踏入医药行业创业有两条路可以选，一条路是原创研发，利用公司自己内部的研发实力获得具有竞争力的创新药；另一条路则是通过外部引进的方式来完善公司的研发管线。\n　　在十年前，当时中国医药行业的新药研究和开发可谓“一穷二白”。夏瑜还是选择了原创的路。\n　　即便近年来，随着一批海归创业者的回归，事实上带动了个体先进技术的回归。但如何带动整体医药行业在中国去深耕建设，如何在中国建立真正先进的研发体系，夏瑜一直在思考与实践。没有急于一时，甚至是牺牲了生产先进产品的时机，夏瑜带领康方生物选择在创立之初，就投入巨大精力，在内部创建一体化的研发体系。\n　　只有在这样的创新研发体系下，具有这种意愿和理想去成长，从研发源头一直做到产业化，未来中国的辉瑞、中国的强生才会出现。\n\n\n\n　　康方生物广州基地外景\n　　图片来源：DR\n　　2012年成立至今，康方生物从最高端的源头科研创新入手，一直到生产、商业化和临床各产业阶段布局，专注开发全球最前沿的肿瘤免疫治疗抗体。目前，康方生物已经开发了超过20个创新候选药物，其中13款创新抗体新药处于临床研究阶段。\n　　“其实不做原创新药也是无可厚非的一种商业模式。唯一我认为出问题的地方是，这个事情变成了红海，而任何事情走入红海就会很可怕。”在中国，药品监管面临的一个产业现实是，即使到了2016年，全国制药企业研发投入总和仍不及全球最大制药企业一家。\n　　“一方面要形成培育产业发展的土壤，另一方面一定要建立优胜劣汰的竞争机制。美国现在的医药巨头，也是经历了产业发展和市场竞争后优胜劣汰的结果。在中国，未来也要出现这样的景象。”夏瑜说。\n　　冰火两重天，资本双刃剑\n　　即便近两年间，随着港交所新股上市制度改革及科创板注册制的推出，给面向市场不同、投资人构成不同、进退出机制考量不同的医药企业，提供了全新的融资机会和更多元的选择。不变的是，创业的商业模式都要能经得起资本保值增值能力的考验。\n　　夏瑜回顾，在创业初期，如果我们当时真的是得不到资本市场的资金支持，可能也会通过其它方式存活下来，但是可以肯定的是，远不可能实现现在的飞速发展。资本其实很大的一个作用是助力，加快企业的发展速度，让企业在竞争的环境中可以更加专心地构建资深的创新竞争力。”\n　　创业公司在每一个发展阶段所选择的商业模式在不同的发展阶段会有不同的体现。\n　　在创业之初2012年，药物创新企业在资本市场并不像现在这样备受追捧。为了生存和继续发展，2015年底，夏瑜决定将康方生物的一个创新产品授权给巨头默沙东。“我觉得从商业模式来讲，在那个时刻一定是一个利于公司长期发展的决定，支撑了我们走向长期发展。”另一方面，这是中国第一款本土企业自主研发的创新抗体药物授权给国际TOP5的制药巨头，也成为中国创新药物产业真正走向国际，并受到国际认可的一个标志性事件之一，也让康方生物在首次登上了药物创新的世界舞台。\n\n\n\n　　生产车间\n　　图片来源：DR\n　　“其实我很理解资本市场。在创业前期我们花了大量的时间做平台的开发，所以才有现在平台上很多的成果收获。时下的康方，我们在高效推进现有管线的临床发展的同时，在产品开发会更聚焦世界前沿的靶点药物。因为我们已经有了很好的产品基础、开发经验，也获得了投资人的认可。但如果我在什么产品都没有的情况下，拿着投资人的钱去做10年的创新研发，试问哪个投资人能答应？”\n　　如果说一种新药的诞生是产业链上各个公司的接力赛，夏瑜决心做的是一场马拉松。\n　　从只身海外求学到归国创业市值500亿\n　　一个值得关注的现象是，在医药行业崭露头角的创新公司中，近20%的创始人是女性。积累了资深的生物药物研究开发经历，作为抗体药物研发专家，夏瑜决定归国创业，与其他3名海归人士创立康方生物。夏瑜作为董事长，是管理团队中唯一一名女性。\n　　夏瑜说：“女性更包容，女性更有韧劲，对一件事情的执着和坚持。”\n　　“但是任何的完美都是相对的，创业没有完美人设。”\n　　就像夏瑜最初决定回国创业，即便得到了女儿家人的支持，仍要面对周遭的不解。已为人母，在女儿成长的关键阶段难道不应该全身心陪伴？作为一名女性，为什么在生活舒适的中年还要再去折腾所谓的事业？\n　　带着不被理解的刺痛，夏瑜和女儿一起蜕变、成长。如今，女儿说，妈妈是自己最崇拜的人。\n　　此时，距离夏瑜一腔孤勇创立康方生物已逾十年。\n　　继2020年康方生物在港交所正式挂牌上市，如今总市值一度冲击550亿港元。\n　　回顾曾经的青春岁月，学霸出身的夏瑜说，“大学一毕业我就出国了。那个时候完全是靠自己拿到一份奖学金，都没揣几块钱就跑出国门，到国外一看跟国内真的是天壤之别。当时很忐忑，不知道接下来会怎么样。”\n　　此后20年间，夏瑜在中美冠科生物、PDL BioPharma、德国拜耳、CrownBio等跨国制药公司担任管理职务，并在英国格拉斯哥大学完成博士后研究工作后，于美国路易斯维尔大学医学院进行科学研究；在担任中美冠科生物技术高级副总裁期间，为公司制定和执行战略以及与辉瑞建立合资企业方面发挥了决定性作用。\n\n\n\n　　夏瑜博士\n　　图片来源：DR\n　　在创始团队中，夏瑜负责公司总体战略规划、业务和科学发展方向。夏瑜说：“在企业发展的抉择时刻，需要的就是拍板的勇气，承担决策的压力和责任。确实考验领导者的深谋远虑和对企业发展的把控。”\n　　在“原创研发路线”战役取得丰硕成果之后，如今夏瑜带领着康方生物要面临的下一个挑战：产品商业化，从biotech走向为biopharma。\n　　在夏瑜看来，“有一些公司可能从创业之初就非常明确说不涉及生产，不涉及未来的商业化，就做自己擅长的事，这也是一种很好的商业模式。但有一些企业，比如康方生物，其实我是没有为未来设限的，只要条件允许，符合公司发展战略，我们就推进。\n　　第一个条件，比如说我是有足够的人才和能力去把生产和商业化都做起来，这就需要一个更大的企业发展目标来推动了。另外，作为创始人，我也要有这个理想，我觉得这非常重要。因为越做到生产和商业化这个阶段，某种意义上说不可控性更强，勇气是必须要有的。”\n　　明知山有虎，偏向虎山行。这就是夏瑜的执着与坚韧。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：刘万里 SF014","news_type":1,"symbols_score_info":{"09926":1}},"isVote":1,"tweetType":1,"viewCount":3374,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":171666399,"gmtCreate":1626742493411,"gmtModify":1703764212411,"author":{"id":"3583528354923579","authorId":"3583528354923579","name":"锐哥来了","avatar":"https://static.tigerbbs.com/86eb4f1a6da7a549e0c096e4e1890a8e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583528354923579","authorIdStr":"3583528354923579"},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/171666399","repostId":"1159080706","repostType":4,"repost":{"id":"1159080706","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1626709038,"share":"https://ttm.financial/m/news/1159080706?lang=en_US&edition=fundamental","pubTime":"2021-07-19 23:37","market":"us","language":"zh","title":"[Movement] Recovering today's lost ground, Wei Xiaoli stopped falling and rebounded","url":"https://stock-news.laohu8.com/highlight/detail?id=1159080706","media":"老虎资讯综合","summary":"7月19日，理想汽车、蔚来、小鹏汽车止跌回升，收复今日失地。\n小鹏汽车此前公布旗下搭载量产车规级激光雷达的小鹏P5的预售价格，并宣布开启预售，小鹏P5新车预售价格16-23万元，共推出6个不同续航配置","content":"<p>On July 19,<a href=\"https://laohu8.com/S/LI\">Li Auto</a>、<a href=\"https://laohu8.com/S/NIO\">Nio</a>、<a href=\"https://laohu8.com/S/XPEV\">XPeng Motors</a>Stop falling and recover today's lost ground.</p><p>XPeng Automobile previously announced the pre-sale price of its XPeng P5 equipped with mass-produced car-grade lidar, and announced the opening of pre-sale. The pre-sale price of XPeng P5 new car is 160,000-230,000 yuan, and a total of six versions with different endurance configurations are available to choose from, with the maximum endurance reaching 600 kilometers under NEDC conditions.</p><p>At the same time, XPeng Automobile issued an announcement to issue 12,083,300 shares at an issue price of HK$165 per share on 19 July 2021 pursuant to the partial exercise of the over-allotment option.</p><p><img src=\"https://static.tigerbbs.com/f72a193fe4e67d7c18a4cbdff58c6864\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>[Movement] Recovering today's lost ground, Wei Xiaoli stopped falling and rebounded</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n[Movement] Recovering today's lost ground, Wei Xiaoli stopped falling and rebounded\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-07-19 23:37</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>On July 19,<a href=\"https://laohu8.com/S/LI\">Li Auto</a>、<a href=\"https://laohu8.com/S/NIO\">Nio</a>、<a href=\"https://laohu8.com/S/XPEV\">XPeng Motors</a>Stop falling and recover today's lost ground.</p><p>XPeng Automobile previously announced the pre-sale price of its XPeng P5 equipped with mass-produced car-grade lidar, and announced the opening of pre-sale. The pre-sale price of XPeng P5 new car is 160,000-230,000 yuan, and a total of six versions with different endurance configurations are available to choose from, with the maximum endurance reaching 600 kilometers under NEDC conditions.</p><p>At the same time, XPeng Automobile issued an announcement to issue 12,083,300 shares at an issue price of HK$165 per share on 19 July 2021 pursuant to the partial exercise of the over-allotment option.</p><p><img src=\"https://static.tigerbbs.com/f72a193fe4e67d7c18a4cbdff58c6864\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/1f36b37eb8e9efe8641c7be55a7da26d","relate_stocks":{"XPEV":"小鹏集团","09868":"小鹏集团-W","NIO":"蔚来","LI":"理想汽车"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1159080706","content_text":"7月19日，理想汽车、蔚来、小鹏汽车止跌回升，收复今日失地。\n小鹏汽车此前公布旗下搭载量产车规级激光雷达的小鹏P5的预售价格，并宣布开启预售，小鹏P5新车预售价格16-23万元，共推出6个不同续航配置的版本可供选择，NEDC工况下最高续航达到600公里。\n同时，小鹏汽车发布公告，于2021年7月19日因部分行使超额配股权而发行1208.33万股，每股发行价为165港元。","news_type":1,"symbols_score_info":{"XPEV":0.9,"LI":0.9,"09868":0.9,"NIO":0.9}},"isVote":1,"tweetType":1,"viewCount":3745,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":171612452,"gmtCreate":1626741721476,"gmtModify":1703764185350,"author":{"id":"3583528354923579","authorId":"3583528354923579","name":"锐哥来了","avatar":"https://static.tigerbbs.com/86eb4f1a6da7a549e0c096e4e1890a8e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583528354923579","authorIdStr":"3583528354923579"},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/171612452","repostId":"2152652777","repostType":4,"isVote":1,"tweetType":1,"viewCount":3447,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":884937555,"gmtCreate":1631845236277,"gmtModify":1676530650956,"author":{"id":"3583528354923579","authorId":"3583528354923579","name":"锐哥来了","avatar":"https://static.tigerbbs.com/86eb4f1a6da7a549e0c096e4e1890a8e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583528354923579","authorIdStr":"3583528354923579"},"themes":[],"title":"","htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/884937555","repostId":"1100031374","repostType":4,"repost":{"id":"1100031374","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631587259,"share":"https://ttm.financial/m/news/1100031374?lang=en_US&edition=fundamental","pubTime":"2021-09-14 10:40","market":"us","language":"zh","title":"Reminder: The Mid-Autumn Festival closure arrangement is here! Hong Kong stocks are closed on the 22nd","url":"https://stock-news.laohu8.com/highlight/detail?id=1100031374","media":"老虎资讯综合","summary":"2021年中秋节假期即将来临！各主要市场休市安排如下：港股：\n\n\n9月22日（周三）休市。9月23日（周四）起照常开市。\n\n\nA股：\n\n\n9月20日（周一）至9月21日（周二）休市。9月22日（周三）起照常开市。\n\n\n美股、英股、澳股、新加坡股市照常交易。\n\n\n沪股通和深股通：\n\n\n9月17日（周五）至9月22日（周三）关闭。9月23日（周四）起照常开通。\n\n\n港股通：\n\n\n9月16日（周四）至9月22日（周三）关闭。9月23日（周四）起照常开通。","content":"<p>The 2021 Mid-Autumn Festival holiday is upon us! The closure arrangements for each of the major markets are as follows:<img src=\"https://static.tigerbbs.com/a514042f0cc485274181ed3db4bcf541\" tg-width=\"1103\" tg-height=\"746\" width=\"100%\" height=\"auto\"><b>Hong Kong stocks:</b></p><p>Closed on Wednesday, September 22. The market will open as usual from September 23rd (Thursday).</p><p><b>A shares:</b></p><p>Closed from Monday, September 20th to Tuesday, September 21st. The market will open as usual from September 22nd (Wednesday).</p><p><b>US stocks, UK stocks, Australian stocks and Singapore stocks traded as usual.</b></p><p><b>Shanghai Stock Connect and Shenzhen Stock Connect:</b></p><p>Closed from Friday, September 17 to Wednesday, September 22. It will be open as usual from Thursday, September 23rd.</p><p><b>Hong Kong Stock Connect:</b></p><p>Closed Thursday, Sept. 16 through Wednesday, Sept. 22. It will be open as usual from Thursday, September 23rd.</p><p><img src=\"https://static.tigerbbs.com/75ca986d45037f1a0b113e295b82f3f9\" tg-width=\"2048\" tg-height=\"1311\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Reminder: The Mid-Autumn Festival closure arrangement is here! Hong Kong stocks are closed on the 22nd</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nReminder: The Mid-Autumn Festival closure arrangement is here! Hong Kong stocks are closed on the 22nd\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-09-14 10:40</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>The 2021 Mid-Autumn Festival holiday is upon us! The closure arrangements for each of the major markets are as follows:<img src=\"https://static.tigerbbs.com/a514042f0cc485274181ed3db4bcf541\" tg-width=\"1103\" tg-height=\"746\" width=\"100%\" height=\"auto\"><b>Hong Kong stocks:</b></p><p>Closed on Wednesday, September 22. The market will open as usual from September 23rd (Thursday).</p><p><b>A shares:</b></p><p>Closed from Monday, September 20th to Tuesday, September 21st. The market will open as usual from September 22nd (Wednesday).</p><p><b>US stocks, UK stocks, Australian stocks and Singapore stocks traded as usual.</b></p><p><b>Shanghai Stock Connect and Shenzhen Stock Connect:</b></p><p>Closed from Friday, September 17 to Wednesday, September 22. It will be open as usual from Thursday, September 23rd.</p><p><b>Hong Kong Stock Connect:</b></p><p>Closed Thursday, Sept. 16 through Wednesday, Sept. 22. It will be open as usual from Thursday, September 23rd.</p><p><img src=\"https://static.tigerbbs.com/75ca986d45037f1a0b113e295b82f3f9\" tg-width=\"2048\" tg-height=\"1311\" referrerpolicy=\"no-referrer\"></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/75ca986d45037f1a0b113e295b82f3f9","relate_stocks":{},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100031374","content_text":"2021年中秋节假期即将来临！各主要市场休市安排如下：港股：\n9月22日（周三）休市。9月23日（周四）起照常开市。\nA股：\n9月20日（周一）至9月21日（周二）休市。9月22日（周三）起照常开市。\n美股、英股、澳股、新加坡股市照常交易。\n沪股通和深股通：\n9月17日（周五）至9月22日（周三）关闭。9月23日（周四）起照常开通。\n港股通：\n9月16日（周四）至9月22日（周三）关闭。9月23日（周四）起照常开通。","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":4642,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":171612452,"gmtCreate":1626741721476,"gmtModify":1703764185350,"author":{"id":"3583528354923579","authorId":"3583528354923579","name":"锐哥来了","avatar":"https://static.tigerbbs.com/86eb4f1a6da7a549e0c096e4e1890a8e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583528354923579","authorIdStr":"3583528354923579"},"themes":[],"title":"","htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/171612452","repostId":"2152652777","repostType":4,"isVote":1,"tweetType":1,"viewCount":3447,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":884998842,"gmtCreate":1631844289386,"gmtModify":1676530650623,"author":{"id":"3583528354923579","authorId":"3583528354923579","name":"锐哥来了","avatar":"https://static.tigerbbs.com/86eb4f1a6da7a549e0c096e4e1890a8e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583528354923579","authorIdStr":"3583528354923579"},"themes":[],"title":"","htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/884998842","repostId":"1115701930","repostType":4,"repost":{"id":"1115701930","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631842682,"share":"https://ttm.financial/m/news/1115701930?lang=en_US&edition=fundamental","pubTime":"2021-09-17 09:38","market":"other","language":"zh","title":"Hong Kong domestic insurance stocks generally weakened, with Ping An of China falling more than 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1115701930","media":"老虎资讯综合","summary":"9月17日讯，港股内险股普遍走弱，中国平安跌3.1%，中国人民保险集团跌2.5%，中国太保、中国太平跌超2%。","content":"<p><img src=\"https://static.tigerbbs.com/62fb8bf9e6b0319be20ba231a920a5d8\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\">On September 17th, insurance stocks in Hong Kong stocks generally weakened.<a href=\"https://laohu8.com/S/021318\">Ping An of China</a>down 3.1%,<a href=\"https://laohu8.com/S/01339\">The People's Insurance Company of China</a>down 2.5%,<a href=\"https://laohu8.com/S/601601\">China Pacific Insurance</a>、<a href=\"https://laohu8.com/S/00966\">China Taiping</a>It fell by more than 2%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong domestic insurance stocks generally weakened, with Ping An of China falling more than 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong domestic insurance stocks generally weakened, with Ping An of China falling more than 3%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-09-17 09:38</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><img src=\"https://static.tigerbbs.com/62fb8bf9e6b0319be20ba231a920a5d8\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\">On September 17th, insurance stocks in Hong Kong stocks generally weakened.<a href=\"https://laohu8.com/S/021318\">Ping An of China</a>down 3.1%,<a href=\"https://laohu8.com/S/01339\">The People's Insurance Company of China</a>down 2.5%,<a href=\"https://laohu8.com/S/601601\">China Pacific Insurance</a>、<a href=\"https://laohu8.com/S/00966\">China Taiping</a>It fell by more than 2%.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/082208e3c37780dd55878056410ffa43","relate_stocks":{"601318":"中国平安","02318":"中国平安","03145":"华夏亚洲高息股","LU":"陆金所"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1115701930","content_text":"9月17日讯，港股内险股普遍走弱，中国平安跌3.1%，中国人民保险集团跌2.5%，中国太保、中国太平跌超2%。","news_type":1,"symbols_score_info":{"601318":0.9,"03145":0.9,"LU":0.9,"02318":0.9}},"isVote":1,"tweetType":1,"viewCount":4303,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":819933613,"gmtCreate":1630026305032,"gmtModify":1676530202919,"author":{"id":"3583528354923579","authorId":"3583528354923579","name":"锐哥来了","avatar":"https://static.tigerbbs.com/86eb4f1a6da7a549e0c096e4e1890a8e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583528354923579","authorIdStr":"3583528354923579"},"themes":[],"title":"","htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/819933613","repostId":"1123728452","repostType":2,"isVote":1,"tweetType":1,"viewCount":3398,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":801885858,"gmtCreate":1627508922774,"gmtModify":1703491180130,"author":{"id":"3583528354923579","authorId":"3583528354923579","name":"锐哥来了","avatar":"https://static.tigerbbs.com/86eb4f1a6da7a549e0c096e4e1890a8e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583528354923579","authorIdStr":"3583528354923579"},"themes":[],"title":"","htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/801885858","repostId":"2154992231","repostType":2,"repost":{"id":"2154992231","kind":"news","pubTimestamp":1627378800,"share":"https://ttm.financial/m/news/2154992231?lang=en_US&edition=fundamental","pubTime":"2021-07-27 17:40","market":"hk","language":"zh","title":"Forbes China Exclusive Interview with Xia Yu, Chairman of Kangfang Bio: Preference to Tiger Mountain Travel","url":"https://stock-news.laohu8.com/highlight/detail?id=2154992231","media":"财经自媒体","summary":"　　康方生物有限公司创始人、董事长夏瑜向福布斯中国表示：“中国医药创新真正的崛起，必须依靠自身实力，培育创新氛围，打造创新体系，实现创新成果突破。从全球行业发展的商业模式来看，买买买的模式一点问题都没有，但像辉瑞、强生、阿斯利康、诺和诺德这类医药行业领军巨头企业，在国际上有一席之地的医药企业，中国要不要出现？”　　今年4月，康方生物公布了上市后的首份年度成绩单。","content":"<p><html><body><div><p cms-style=\"font-L\">Source: Forbes</p><p><p cms-style=\"font-L\">The track of pharmaceutical innovation,<a href=\"https://laohu8.com/S/PFE\">Pfizer</a>、<a href=\"https://laohu8.com/S/JNJ\">Johnson & Johnson</a>、<a href=\"https://laohu8.com/S/AZN\">AstraZeneca</a>、<a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>When there are many international giants, it may not be feasible to sharpen a sword in ten years.</p><p><p cms-style=\"font-L\">Xia Yu, founder and chairman of Kangfang Biological Co., Ltd., told Forbes China: \"<span><a href=\"https://laohu8.com/S/600056\">CHINA PHARMA</a></span><span></span>The real rise of innovation must rely on its own strength, cultivate an innovative atmosphere, build an innovative system, and achieve breakthroughs in innovative achievements. From the perspective of the business model of global industry development, there is no problem with the buy-buy-buy model at all, but leading giants in the pharmaceutical industry such as Pfizer, Johnson & Johnson, AstraZeneca, and Novo Nordisk, pharmaceutical companies with a place in the world, should China appear? \"</p><p><p cms-style=\"font-L\">\"China should emerge.\" Xia Yu was firm, and the R&D and innovation capabilities of these enterprises themselves are the key to becoming world-class leaders.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/324/w550h574/20210727/9053-eb59dd1acbf005315f9f014538a392da.jpg\"/><span></span></div></div><p cms-style=\"font-L\">Xia Yu, Founder and Chairman of Kangfang Biological Co., Ltd.</p><p><p cms-style=\"font-L align-right\">Credit: DR</p><p><p cms-style=\"font-L\">However, where should Chinese pharmaceutical companies that can compete with or even surpass giants place their hopes?</p><p><p cms-style=\"font-L\">In April this year, Kangfang Bio announced its first annual report card after listing. The announcement shows that by the end of 2020, Kangfang Bio's other income and gains exceeded 100 million yuan; R&D investment reached 764.5 million yuan.</p><p><p cms-style=\"font-L\">Ten years after its founding, Kangfang Bio has finally developed a pioneer track in the research and development of original antibody drugs in China: among more than 20 drugs under development, 6 bispecific antibodies with the world's first or leading progress, and a number of candidate drugs with the most cutting-edge targets. The research and development progress is leading in the world, with more than 20 clinical research projects in clinical phase II and later stages, and the core world's first double antibody is about to be listed... A Chinese biotechnology company that has actually gone abroad through self-research and development has quietly risen.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/80/w550h330/20210727/0264-3242e677075ee7bd62b8859c7068fc7c.jpg\"/><span></span></div></div><p cms-style=\"font-L\">The world's first double antibody cadonilimab</p><p><p cms-style=\"font-L align-right\">Credit: DR</p><p><p cms-style=\"font-L\">　　<font cms-style=\"font-L strong-Bold\">Buy, buy, buy mode, can't buy China's Pfizer, China's Johnson & Johnson</font></p><p><p cms-style=\"font-L\">More than a decade ago, Xia Yu, who had struggled to make a comfortable and superior life in a foreign country, returned to China, and the idea of starting a business emerged among the bustling crowds in Beijing. As a Chinese, Xia Yu's first question is, does China need original new drugs? Can the Chinese only use foreign outdated medicines from ten years ago for decades?</p><p><p cms-style=\"font-L\">\"In fact, if I do the same thing (pharmaceutical R&D) in the United States, I will likely not do it at a certain stage of R&D.\" Xia Yu further said: \"Because I know very well that the investment in production and commercialization and even clinical trials after R&D is too huge. But today, with the development of the domestic pharmaceutical industry, whether from the perspective of capital market development or industrial policy support, China actually has the possibility to capture the global industry highland.\"</p><p><p cms-style=\"font-L\">Of course, for Chinese pharmaceutical companies, a natural shortcoming in participating in global competition is that they started late and the overall development level of the industry is relatively backward. \"But a gap doesn't mean that we can't lead the world in certain fields, certain directions and certain stages.\"</p><p><p cms-style=\"font-L\">Xia Yu knows very well that there are two ways to choose from when entering the pharmaceutical industry to start a business. One way is original R&D, using the company's own internal R&D strength to obtain competitive innovative drugs; Another way is to improve the company's R&D pipeline through external introduction.</p><p><p cms-style=\"font-L\">Ten years ago, the research and development of new drugs in China's pharmaceutical industry at that time could be described as \"poor and white\". Xia Yu still chose the original road.</p><p><p cms-style=\"font-L\">Even in recent years, with the return of a group of returned entrepreneurs, it has actually driven the return of individual advanced technologies. However, Xia Yu has been thinking and practicing how to drive the overall pharmaceutical industry to deeply cultivate and build in China, and how to establish a truly advanced R&D system in China. Without rushing for a while, or even sacrificing the opportunity to produce advanced products, Xia Yu led Kangfang Bio to invest a lot of energy in creating an integrated R&D system internally at the beginning of its establishment.</p><p><p cms-style=\"font-L\">Only under such an innovative R&D system, with this willingness and ideal to grow, and from the source of R&D to industrialization, will China's Pfizer and China's Johnson & Johnson appear in the future.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/40/w550h290/20210727/55da-1b43fa5d55b5db075d491294cb78bfd6.png\"/><span></span></div></div><p cms-style=\"font-L\">Exterior view of Kangfang Biotech Guangzhou Base</p><p><p cms-style=\"font-L align-right\">Credit: DR</p><p><p cms-style=\"font-L\">Since its establishment in 2012, Kangfang Bio has started from the highest-end source scientific research and innovation, until the layout of production, commercialization and clinical industrial stages, focusing on the development of the world's most cutting-edge tumor immunotherapy antibodies. At present, Kangfang Bio has developed more than 20 innovative drug candidates, of which 13 innovative antibody new drugs are in the clinical research stage.</p><p><p cms-style=\"font-L\">\"In fact, not making original new drugs is an understandable business model. The only thing I think is wrong is that this thing has become a Red Sea, and anything that goes into the Red Sea will be terrible.\" In China, an industrial reality faced by drug supervision is that even by 2016, the total R&D investment of pharmaceutical companies nationwide is still less than that of the world's largest pharmaceutical companies.</p><p><p cms-style=\"font-L\">\"On the one hand, it is necessary to form a soil for cultivating industrial development, and on the other hand, it is necessary to establish a competitive mechanism for the survival of the fittest. The current pharmaceutical giants in the United States are also the result of the survival of the fittest after experiencing industrial development and market competition. In China, such a scene will also appear in the future.\" Xia Yu said.</p><p><p cms-style=\"font-L\">　　<font cms-style=\"font-L strong-Bold\">The two heavens of ice and fire, the double-edged sword of capital</font></p><p><p cms-style=\"font-L\">Even in the past two years, with the reform of the new stock listing system of the Hong Kong Stock Exchange and the introduction of the registration system of the Science and Technology Innovation Board, new financing opportunities and more diversified choices have been provided for pharmaceutical companies with different markets, different investor compositions and different entry and exit mechanisms. What remains unchanged is that the business model of entrepreneurship must be able to stand the test of capital preservation and appreciation ability.</p><p><p cms-style=\"font-L\">Xia Yu recalled that in the early days of starting a business, if we really didn't get the financial support of the capital market at that time, we might have survived in other ways, but what is certain is that it is far from possible to achieve the current rapid development. In fact, a great role of capital is to help accelerate the development of enterprises, so that enterprises can focus more on building senior innovation competitiveness in a competitive environment. \"</p><p><p cms-style=\"font-L\">　　<a href=\"https://laohu8.com/S/V03.SI\">Startups</a>The business model chosen at each stage of development will have different embodiments at different stages of development.</p><p><p cms-style=\"font-L\">At the beginning of the business in 2012, drug innovation companies were not as sought after in the capital market as they are now. In order to survive and continue to develop, at the end of 2015, Xia Yu decided to license an innovative product of Kangfang Bio to the giant<a href=\"https://laohu8.com/S/MRK\">Merck</a>。 \"I think from the perspective of business model, at that moment, it must be a decision conducive to the long-term development of the company, which supports our long-term development.\" On the other hand, this is China's first innovative antibody drug independently developed by a local company to be licensed to the international TOP5 pharmaceutical giant, and it has also become one of the landmark events that China's innovative drug industry has truly gone global and been recognized internationally. It has also allowed Kangfang Bio to enter the world stage of drug innovation for the first time.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/117/w550h367/20210727/b886-3bb61d586babf8c3cb5f2b87668503b0.jpg\"/><span></span></div></div><p cms-style=\"font-L\">Production workshop</p><p><p cms-style=\"font-L align-right\">Credit: DR</p><p><p cms-style=\"font-L\">\"Actually, I understand the capital market very well. In the early stage of starting the business, we spent a lot of time developing the platform, so we have gained a lot of results on the platform now. Nowadays, Kangfang, while efficiently promoting the clinical development of the existing pipeline, we will focus more on the world's cutting-edge target drugs in product development. Because we already have a good product foundation and development experience, we have also been recognized by investors. But if I take investors' money to do 10 years of innovative research and development without any products, which investor can agree? \"</p><p><p cms-style=\"font-L\">If the birth of a new drug is a relay race for various companies in the industrial chain, Xia Yu is determined to do a marathon.</p><p><p cms-style=\"font-L\">　　<font cms-style=\"font-L strong-Bold\">From studying overseas alone to returning home to start a business with a market value of 50 billion</font></p><p><p cms-style=\"font-L\">A phenomenon of concern is that nearly 20% of the founders of innovative companies emerging in the pharmaceutical industry are women. Having accumulated senior experience in biological drug research and development, as an expert in antibody drug research and development, Xia Yu decided to return to China to start a business, and founded Kangfang Bio with three other returnees. Xia Yu, as the chairman, is the only woman in the management team.</p><p><p cms-style=\"font-L\">Xia Yu said: \"Women are more tolerant, women are more resilient, and they are persistent and persistent in one thing.\"</p><p><p cms-style=\"font-L\">\"But any perfection is relative, and there is no perfect person for entrepreneurship.\"</p><p><p cms-style=\"font-L\">Just like Xia Yu initially decided to return to China to start a business, even with the support of her daughter's family, she still had to face the confusion around her. As a mother, shouldn't she be fully accompanied by her daughter during the critical stage of her growth? As a woman, why do you have to toss the so-called career again in a comfortable middle age?</p><p><p cms-style=\"font-L\">With the sting of not being understood, Xia Yu and her daughter transformed and grew up together. Nowadays, my daughter said, her mother is the person she admires the most.</p><p><p cms-style=\"font-L\">At this time, it has been more than ten years since Xia Yu founded Kangfang Bio alone.</p><p><p cms-style=\"font-L\">Following the official listing of Kangfang Bio on the Hong Kong Stock Exchange in 2020, the total market value once hit HK$55 billion.</p><p><p cms-style=\"font-L\">Looking back at his youth, Xia Yu, who was born as a master, said, \"I went abroad as soon as I graduated from college. At that time, I got a scholarship completely by myself, and I ran abroad without a few dollars. When I went abroad, it was really different from China. At that time, I was very nervous, and I didn't know what would happen next.\"</p><p><p cms-style=\"font-L\">In the next 20 years, Xia Yu worked in Sino-US Crown Biotech,<a href=\"https://laohu8.com/S/PDLI\">PDL BioPharma</a>He held management positions in multinational pharmaceutical companies such as Bayer and CrownBio in Germany, and conducted scientific research at the University of Louisville School of Medicine in the United States after completing postdoctoral research at the University of Glasgow in the United Kingdom; Played a decisive role in developing and executing strategies for the company and establishing a joint venture with Pfizer during his tenure as Senior Vice President of Mid-US Corontech Biotechnology.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/462/w550h712/20210727/7570-3cd7c1d54dc532007a1a67b35d002611.jpg\"/><span></span></div></div><p cms-style=\"font-L\">Dr. Xia Yu</p><p><p cms-style=\"font-L align-right\">Credit: DR</p><p><p cms-style=\"font-L\">Within the founding team, Xia Yu is responsible for the overall strategic planning, business and scientific development direction of the company. Xia Yu said, \"At the moment of choice of enterprise development, what is needed is the courage to make a decision and bear the pressure and responsibility of decision-making. It does test the leader's foresight and control of enterprise development.\"</p><p><p cms-style=\"font-L\">After the fruitful results of the \"original R&D route\" campaign, Xia Yu now leads the next challenge that Kangfang Bio will face: product commercialization, from biotech to biopharma.</p><p><p cms-style=\"font-L\">In Xia Yu's view, \"Some companies may have made it very clear from the beginning of their business that they don't involve production or future commercialization, so they do what they are good at. This is also a good business model. But there are some companies, such as Kangfang Bio, in fact, I don't set limits for the future. As long as conditions allow and in line with the company's development strategy, we will push forward.</p><p><p cms-style=\"font-L\">The first condition, for example, I have enough talents and abilities to do both production and commercialization, which requires a larger enterprise development goal to promote. In addition, as a founder, I also want to have this ideal, which I think is very important. Because the more we achieve this stage of production and commercialization, the more uncontrollable it is in a sense, and courage is necessary. \"</p><p><p cms-style=\"font-L\">Knowing that there are tigers in the mountains, they prefer to go to the tiger This is Xia Yu's persistence and tenacity.</p><p><div><div><img src=\"\"/></div><div>Massive information, accurate interpretation, all in<a href=\"https://laohu8.com/S/SINA\">SINA</a>Finance APP</div></div>Editor in charge: Liu Wanli SF014</p><p></div></body></html></p>","source":"sina","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Forbes China Exclusive Interview with Xia Yu, Chairman of Kangfang Bio: Preference to Tiger Mountain Travel</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForbes China Exclusive Interview with Xia Yu, Chairman of Kangfang Bio: Preference to Tiger Mountain Travel\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">财经自媒体</strong><span class=\"h-time small\">2021-07-27 17:40</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><body><div><p cms-style=\"font-L\">Source: Forbes</p><p><p cms-style=\"font-L\">The track of pharmaceutical innovation,<a href=\"https://laohu8.com/S/PFE\">Pfizer</a>、<a href=\"https://laohu8.com/S/JNJ\">Johnson & Johnson</a>、<a href=\"https://laohu8.com/S/AZN\">AstraZeneca</a>、<a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>When there are many international giants, it may not be feasible to sharpen a sword in ten years.</p><p><p cms-style=\"font-L\">Xia Yu, founder and chairman of Kangfang Biological Co., Ltd., told Forbes China: \"<span><a href=\"https://laohu8.com/S/600056\">CHINA PHARMA</a></span><span></span>The real rise of innovation must rely on its own strength, cultivate an innovative atmosphere, build an innovative system, and achieve breakthroughs in innovative achievements. From the perspective of the business model of global industry development, there is no problem with the buy-buy-buy model at all, but leading giants in the pharmaceutical industry such as Pfizer, Johnson & Johnson, AstraZeneca, and Novo Nordisk, pharmaceutical companies with a place in the world, should China appear? \"</p><p><p cms-style=\"font-L\">\"China should emerge.\" Xia Yu was firm, and the R&D and innovation capabilities of these enterprises themselves are the key to becoming world-class leaders.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/324/w550h574/20210727/9053-eb59dd1acbf005315f9f014538a392da.jpg\"/><span></span></div></div><p cms-style=\"font-L\">Xia Yu, Founder and Chairman of Kangfang Biological Co., Ltd.</p><p><p cms-style=\"font-L align-right\">Credit: DR</p><p><p cms-style=\"font-L\">However, where should Chinese pharmaceutical companies that can compete with or even surpass giants place their hopes?</p><p><p cms-style=\"font-L\">In April this year, Kangfang Bio announced its first annual report card after listing. The announcement shows that by the end of 2020, Kangfang Bio's other income and gains exceeded 100 million yuan; R&D investment reached 764.5 million yuan.</p><p><p cms-style=\"font-L\">Ten years after its founding, Kangfang Bio has finally developed a pioneer track in the research and development of original antibody drugs in China: among more than 20 drugs under development, 6 bispecific antibodies with the world's first or leading progress, and a number of candidate drugs with the most cutting-edge targets. The research and development progress is leading in the world, with more than 20 clinical research projects in clinical phase II and later stages, and the core world's first double antibody is about to be listed... A Chinese biotechnology company that has actually gone abroad through self-research and development has quietly risen.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/80/w550h330/20210727/0264-3242e677075ee7bd62b8859c7068fc7c.jpg\"/><span></span></div></div><p cms-style=\"font-L\">The world's first double antibody cadonilimab</p><p><p cms-style=\"font-L align-right\">Credit: DR</p><p><p cms-style=\"font-L\">　　<font cms-style=\"font-L strong-Bold\">Buy, buy, buy mode, can't buy China's Pfizer, China's Johnson & Johnson</font></p><p><p cms-style=\"font-L\">More than a decade ago, Xia Yu, who had struggled to make a comfortable and superior life in a foreign country, returned to China, and the idea of starting a business emerged among the bustling crowds in Beijing. As a Chinese, Xia Yu's first question is, does China need original new drugs? Can the Chinese only use foreign outdated medicines from ten years ago for decades?</p><p><p cms-style=\"font-L\">\"In fact, if I do the same thing (pharmaceutical R&D) in the United States, I will likely not do it at a certain stage of R&D.\" Xia Yu further said: \"Because I know very well that the investment in production and commercialization and even clinical trials after R&D is too huge. But today, with the development of the domestic pharmaceutical industry, whether from the perspective of capital market development or industrial policy support, China actually has the possibility to capture the global industry highland.\"</p><p><p cms-style=\"font-L\">Of course, for Chinese pharmaceutical companies, a natural shortcoming in participating in global competition is that they started late and the overall development level of the industry is relatively backward. \"But a gap doesn't mean that we can't lead the world in certain fields, certain directions and certain stages.\"</p><p><p cms-style=\"font-L\">Xia Yu knows very well that there are two ways to choose from when entering the pharmaceutical industry to start a business. One way is original R&D, using the company's own internal R&D strength to obtain competitive innovative drugs; Another way is to improve the company's R&D pipeline through external introduction.</p><p><p cms-style=\"font-L\">Ten years ago, the research and development of new drugs in China's pharmaceutical industry at that time could be described as \"poor and white\". Xia Yu still chose the original road.</p><p><p cms-style=\"font-L\">Even in recent years, with the return of a group of returned entrepreneurs, it has actually driven the return of individual advanced technologies. However, Xia Yu has been thinking and practicing how to drive the overall pharmaceutical industry to deeply cultivate and build in China, and how to establish a truly advanced R&D system in China. Without rushing for a while, or even sacrificing the opportunity to produce advanced products, Xia Yu led Kangfang Bio to invest a lot of energy in creating an integrated R&D system internally at the beginning of its establishment.</p><p><p cms-style=\"font-L\">Only under such an innovative R&D system, with this willingness and ideal to grow, and from the source of R&D to industrialization, will China's Pfizer and China's Johnson & Johnson appear in the future.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/40/w550h290/20210727/55da-1b43fa5d55b5db075d491294cb78bfd6.png\"/><span></span></div></div><p cms-style=\"font-L\">Exterior view of Kangfang Biotech Guangzhou Base</p><p><p cms-style=\"font-L align-right\">Credit: DR</p><p><p cms-style=\"font-L\">Since its establishment in 2012, Kangfang Bio has started from the highest-end source scientific research and innovation, until the layout of production, commercialization and clinical industrial stages, focusing on the development of the world's most cutting-edge tumor immunotherapy antibodies. At present, Kangfang Bio has developed more than 20 innovative drug candidates, of which 13 innovative antibody new drugs are in the clinical research stage.</p><p><p cms-style=\"font-L\">\"In fact, not making original new drugs is an understandable business model. The only thing I think is wrong is that this thing has become a Red Sea, and anything that goes into the Red Sea will be terrible.\" In China, an industrial reality faced by drug supervision is that even by 2016, the total R&D investment of pharmaceutical companies nationwide is still less than that of the world's largest pharmaceutical companies.</p><p><p cms-style=\"font-L\">\"On the one hand, it is necessary to form a soil for cultivating industrial development, and on the other hand, it is necessary to establish a competitive mechanism for the survival of the fittest. The current pharmaceutical giants in the United States are also the result of the survival of the fittest after experiencing industrial development and market competition. In China, such a scene will also appear in the future.\" Xia Yu said.</p><p><p cms-style=\"font-L\">　　<font cms-style=\"font-L strong-Bold\">The two heavens of ice and fire, the double-edged sword of capital</font></p><p><p cms-style=\"font-L\">Even in the past two years, with the reform of the new stock listing system of the Hong Kong Stock Exchange and the introduction of the registration system of the Science and Technology Innovation Board, new financing opportunities and more diversified choices have been provided for pharmaceutical companies with different markets, different investor compositions and different entry and exit mechanisms. What remains unchanged is that the business model of entrepreneurship must be able to stand the test of capital preservation and appreciation ability.</p><p><p cms-style=\"font-L\">Xia Yu recalled that in the early days of starting a business, if we really didn't get the financial support of the capital market at that time, we might have survived in other ways, but what is certain is that it is far from possible to achieve the current rapid development. In fact, a great role of capital is to help accelerate the development of enterprises, so that enterprises can focus more on building senior innovation competitiveness in a competitive environment. \"</p><p><p cms-style=\"font-L\">　　<a href=\"https://laohu8.com/S/V03.SI\">Startups</a>The business model chosen at each stage of development will have different embodiments at different stages of development.</p><p><p cms-style=\"font-L\">At the beginning of the business in 2012, drug innovation companies were not as sought after in the capital market as they are now. In order to survive and continue to develop, at the end of 2015, Xia Yu decided to license an innovative product of Kangfang Bio to the giant<a href=\"https://laohu8.com/S/MRK\">Merck</a>。 \"I think from the perspective of business model, at that moment, it must be a decision conducive to the long-term development of the company, which supports our long-term development.\" On the other hand, this is China's first innovative antibody drug independently developed by a local company to be licensed to the international TOP5 pharmaceutical giant, and it has also become one of the landmark events that China's innovative drug industry has truly gone global and been recognized internationally. It has also allowed Kangfang Bio to enter the world stage of drug innovation for the first time.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/117/w550h367/20210727/b886-3bb61d586babf8c3cb5f2b87668503b0.jpg\"/><span></span></div></div><p cms-style=\"font-L\">Production workshop</p><p><p cms-style=\"font-L align-right\">Credit: DR</p><p><p cms-style=\"font-L\">\"Actually, I understand the capital market very well. In the early stage of starting the business, we spent a lot of time developing the platform, so we have gained a lot of results on the platform now. Nowadays, Kangfang, while efficiently promoting the clinical development of the existing pipeline, we will focus more on the world's cutting-edge target drugs in product development. Because we already have a good product foundation and development experience, we have also been recognized by investors. But if I take investors' money to do 10 years of innovative research and development without any products, which investor can agree? \"</p><p><p cms-style=\"font-L\">If the birth of a new drug is a relay race for various companies in the industrial chain, Xia Yu is determined to do a marathon.</p><p><p cms-style=\"font-L\">　　<font cms-style=\"font-L strong-Bold\">From studying overseas alone to returning home to start a business with a market value of 50 billion</font></p><p><p cms-style=\"font-L\">A phenomenon of concern is that nearly 20% of the founders of innovative companies emerging in the pharmaceutical industry are women. Having accumulated senior experience in biological drug research and development, as an expert in antibody drug research and development, Xia Yu decided to return to China to start a business, and founded Kangfang Bio with three other returnees. Xia Yu, as the chairman, is the only woman in the management team.</p><p><p cms-style=\"font-L\">Xia Yu said: \"Women are more tolerant, women are more resilient, and they are persistent and persistent in one thing.\"</p><p><p cms-style=\"font-L\">\"But any perfection is relative, and there is no perfect person for entrepreneurship.\"</p><p><p cms-style=\"font-L\">Just like Xia Yu initially decided to return to China to start a business, even with the support of her daughter's family, she still had to face the confusion around her. As a mother, shouldn't she be fully accompanied by her daughter during the critical stage of her growth? As a woman, why do you have to toss the so-called career again in a comfortable middle age?</p><p><p cms-style=\"font-L\">With the sting of not being understood, Xia Yu and her daughter transformed and grew up together. Nowadays, my daughter said, her mother is the person she admires the most.</p><p><p cms-style=\"font-L\">At this time, it has been more than ten years since Xia Yu founded Kangfang Bio alone.</p><p><p cms-style=\"font-L\">Following the official listing of Kangfang Bio on the Hong Kong Stock Exchange in 2020, the total market value once hit HK$55 billion.</p><p><p cms-style=\"font-L\">Looking back at his youth, Xia Yu, who was born as a master, said, \"I went abroad as soon as I graduated from college. At that time, I got a scholarship completely by myself, and I ran abroad without a few dollars. When I went abroad, it was really different from China. At that time, I was very nervous, and I didn't know what would happen next.\"</p><p><p cms-style=\"font-L\">In the next 20 years, Xia Yu worked in Sino-US Crown Biotech,<a href=\"https://laohu8.com/S/PDLI\">PDL BioPharma</a>He held management positions in multinational pharmaceutical companies such as Bayer and CrownBio in Germany, and conducted scientific research at the University of Louisville School of Medicine in the United States after completing postdoctoral research at the University of Glasgow in the United Kingdom; Played a decisive role in developing and executing strategies for the company and establishing a joint venture with Pfizer during his tenure as Senior Vice President of Mid-US Corontech Biotechnology.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/462/w550h712/20210727/7570-3cd7c1d54dc532007a1a67b35d002611.jpg\"/><span></span></div></div><p cms-style=\"font-L\">Dr. Xia Yu</p><p><p cms-style=\"font-L align-right\">Credit: DR</p><p><p cms-style=\"font-L\">Within the founding team, Xia Yu is responsible for the overall strategic planning, business and scientific development direction of the company. Xia Yu said, \"At the moment of choice of enterprise development, what is needed is the courage to make a decision and bear the pressure and responsibility of decision-making. It does test the leader's foresight and control of enterprise development.\"</p><p><p cms-style=\"font-L\">After the fruitful results of the \"original R&D route\" campaign, Xia Yu now leads the next challenge that Kangfang Bio will face: product commercialization, from biotech to biopharma.</p><p><p cms-style=\"font-L\">In Xia Yu's view, \"Some companies may have made it very clear from the beginning of their business that they don't involve production or future commercialization, so they do what they are good at. This is also a good business model. But there are some companies, such as Kangfang Bio, in fact, I don't set limits for the future. As long as conditions allow and in line with the company's development strategy, we will push forward.</p><p><p cms-style=\"font-L\">The first condition, for example, I have enough talents and abilities to do both production and commercialization, which requires a larger enterprise development goal to promote. In addition, as a founder, I also want to have this ideal, which I think is very important. Because the more we achieve this stage of production and commercialization, the more uncontrollable it is in a sense, and courage is necessary. \"</p><p><p cms-style=\"font-L\">Knowing that there are tigers in the mountains, they prefer to go to the tiger This is Xia Yu's persistence and tenacity.</p><p><div><div><img src=\"\"/></div><div>Massive information, accurate interpretation, all in<a href=\"https://laohu8.com/S/SINA\">SINA</a>Finance APP</div></div>Editor in charge: Liu Wanli SF014</p><p></div></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"https://finance.sina.com.cn/chanjing/cyxw/2021-07-27/doc-ikqcfnca9352486.shtml\">财经自媒体</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/bc7ad619aa7e42a7db4703997b65806b","relate_stocks":{"09926":"康方生物"},"source_url":"https://finance.sina.com.cn/chanjing/cyxw/2021-07-27/doc-ikqcfnca9352486.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","article_id":"2154992231","content_text":"来源：福布斯\n　　医药创新这个赛道，辉瑞、强生、阿斯利康、诺和诺德等国际巨头林立，十年磨一剑也未必可行。\n　　康方生物有限公司创始人、董事长夏瑜向福布斯中国表示：“中国医药创新真正的崛起，必须依靠自身实力，培育创新氛围，打造创新体系，实现创新成果突破。从全球行业发展的商业模式来看，买买买的模式一点问题都没有，但像辉瑞、强生、阿斯利康、诺和诺德这类医药行业领军巨头企业，在国际上有一席之地的医药企业，中国要不要出现？”\n　　“中国应该出现。”夏瑜很坚定，而这些企业自身的研发创新能力是企业成为世界级领导者的关键。\n\n\n\n　　康方生物有限公司创始人、董事长夏瑜\n　　图片来源：DR\n　　只是，能与巨头比肩甚至超越巨头的中国医药企业，应该把希望寄托于哪里？\n　　今年4月，康方生物公布了上市后的首份年度成绩单。公告显示，截至2020年底，康方生物其他收入及收益超1亿元；研发投入达到7.645亿元。\n　　创业十年，康方生物终于开拓出一条中国原创抗体药物研发的先行者赛道：20多款在研药物中，6款全球首创或进度领先的双特异性抗体，多款最前沿靶点候选药物研发进度全球领先，超过20个临床研究项目在临床II期及往后阶段，核心全球首创双抗即将上市……一家实打实通过自我研发走出国门的中国生物科技公司悄然崛起。\n\n\n\n　　全球首创双抗cadonilimab\n　　图片来源：DR\n　　买买买模式，买不来中国的辉瑞、中国的强生\n　　十几年前，在异国他乡已打拼出安逸优越生活的夏瑜回国，在北京熙熙攘攘的人群中，冒出创业的念头。作为一名中国人，夏瑜首先想到的问题是，中国是不是需要原创新药？中国人难道只能数十年如一日地用国外十年前的过时药？\n　　“其实，如果我在美国做同样的事情（医药研发），我很有可能做到一个研发某个阶段就不做了。”夏瑜进一步表示：“因为我自己也很清楚，研发后的生产和商业化，甚至临床实验的投入实在太巨大了。但时至今日，随着国内医药行业的发展，无论是从资本市场发展还是产业政策的支持来看，中国其实已经拥有了去攻占全球行业高地的可能。”\n　　当然，参与全球竞争，对于中国医药企业来说，一个天然短板是起步晚、行业整体发展水平相对落后。“但有差距并不代表我们自己在某一些领域、某一些方向、某一些阶段上，就没有办法做到世界领先。”\n　　夏瑜很清楚，踏入医药行业创业有两条路可以选，一条路是原创研发，利用公司自己内部的研发实力获得具有竞争力的创新药；另一条路则是通过外部引进的方式来完善公司的研发管线。\n　　在十年前，当时中国医药行业的新药研究和开发可谓“一穷二白”。夏瑜还是选择了原创的路。\n　　即便近年来，随着一批海归创业者的回归，事实上带动了个体先进技术的回归。但如何带动整体医药行业在中国去深耕建设，如何在中国建立真正先进的研发体系，夏瑜一直在思考与实践。没有急于一时，甚至是牺牲了生产先进产品的时机，夏瑜带领康方生物选择在创立之初，就投入巨大精力，在内部创建一体化的研发体系。\n　　只有在这样的创新研发体系下，具有这种意愿和理想去成长，从研发源头一直做到产业化，未来中国的辉瑞、中国的强生才会出现。\n\n\n\n　　康方生物广州基地外景\n　　图片来源：DR\n　　2012年成立至今，康方生物从最高端的源头科研创新入手，一直到生产、商业化和临床各产业阶段布局，专注开发全球最前沿的肿瘤免疫治疗抗体。目前，康方生物已经开发了超过20个创新候选药物，其中13款创新抗体新药处于临床研究阶段。\n　　“其实不做原创新药也是无可厚非的一种商业模式。唯一我认为出问题的地方是，这个事情变成了红海，而任何事情走入红海就会很可怕。”在中国，药品监管面临的一个产业现实是，即使到了2016年，全国制药企业研发投入总和仍不及全球最大制药企业一家。\n　　“一方面要形成培育产业发展的土壤，另一方面一定要建立优胜劣汰的竞争机制。美国现在的医药巨头，也是经历了产业发展和市场竞争后优胜劣汰的结果。在中国，未来也要出现这样的景象。”夏瑜说。\n　　冰火两重天，资本双刃剑\n　　即便近两年间，随着港交所新股上市制度改革及科创板注册制的推出，给面向市场不同、投资人构成不同、进退出机制考量不同的医药企业，提供了全新的融资机会和更多元的选择。不变的是，创业的商业模式都要能经得起资本保值增值能力的考验。\n　　夏瑜回顾，在创业初期，如果我们当时真的是得不到资本市场的资金支持，可能也会通过其它方式存活下来，但是可以肯定的是，远不可能实现现在的飞速发展。资本其实很大的一个作用是助力，加快企业的发展速度，让企业在竞争的环境中可以更加专心地构建资深的创新竞争力。”\n　　创业公司在每一个发展阶段所选择的商业模式在不同的发展阶段会有不同的体现。\n　　在创业之初2012年，药物创新企业在资本市场并不像现在这样备受追捧。为了生存和继续发展，2015年底，夏瑜决定将康方生物的一个创新产品授权给巨头默沙东。“我觉得从商业模式来讲，在那个时刻一定是一个利于公司长期发展的决定，支撑了我们走向长期发展。”另一方面，这是中国第一款本土企业自主研发的创新抗体药物授权给国际TOP5的制药巨头，也成为中国创新药物产业真正走向国际，并受到国际认可的一个标志性事件之一，也让康方生物在首次登上了药物创新的世界舞台。\n\n\n\n　　生产车间\n　　图片来源：DR\n　　“其实我很理解资本市场。在创业前期我们花了大量的时间做平台的开发，所以才有现在平台上很多的成果收获。时下的康方，我们在高效推进现有管线的临床发展的同时，在产品开发会更聚焦世界前沿的靶点药物。因为我们已经有了很好的产品基础、开发经验，也获得了投资人的认可。但如果我在什么产品都没有的情况下，拿着投资人的钱去做10年的创新研发，试问哪个投资人能答应？”\n　　如果说一种新药的诞生是产业链上各个公司的接力赛，夏瑜决心做的是一场马拉松。\n　　从只身海外求学到归国创业市值500亿\n　　一个值得关注的现象是，在医药行业崭露头角的创新公司中，近20%的创始人是女性。积累了资深的生物药物研究开发经历，作为抗体药物研发专家，夏瑜决定归国创业，与其他3名海归人士创立康方生物。夏瑜作为董事长，是管理团队中唯一一名女性。\n　　夏瑜说：“女性更包容，女性更有韧劲，对一件事情的执着和坚持。”\n　　“但是任何的完美都是相对的，创业没有完美人设。”\n　　就像夏瑜最初决定回国创业，即便得到了女儿家人的支持，仍要面对周遭的不解。已为人母，在女儿成长的关键阶段难道不应该全身心陪伴？作为一名女性，为什么在生活舒适的中年还要再去折腾所谓的事业？\n　　带着不被理解的刺痛，夏瑜和女儿一起蜕变、成长。如今，女儿说，妈妈是自己最崇拜的人。\n　　此时，距离夏瑜一腔孤勇创立康方生物已逾十年。\n　　继2020年康方生物在港交所正式挂牌上市，如今总市值一度冲击550亿港元。\n　　回顾曾经的青春岁月，学霸出身的夏瑜说，“大学一毕业我就出国了。那个时候完全是靠自己拿到一份奖学金，都没揣几块钱就跑出国门，到国外一看跟国内真的是天壤之别。当时很忐忑，不知道接下来会怎么样。”\n　　此后20年间，夏瑜在中美冠科生物、PDL BioPharma、德国拜耳、CrownBio等跨国制药公司担任管理职务，并在英国格拉斯哥大学完成博士后研究工作后，于美国路易斯维尔大学医学院进行科学研究；在担任中美冠科生物技术高级副总裁期间，为公司制定和执行战略以及与辉瑞建立合资企业方面发挥了决定性作用。\n\n\n\n　　夏瑜博士\n　　图片来源：DR\n　　在创始团队中，夏瑜负责公司总体战略规划、业务和科学发展方向。夏瑜说：“在企业发展的抉择时刻，需要的就是拍板的勇气，承担决策的压力和责任。确实考验领导者的深谋远虑和对企业发展的把控。”\n　　在“原创研发路线”战役取得丰硕成果之后，如今夏瑜带领着康方生物要面临的下一个挑战：产品商业化，从biotech走向为biopharma。\n　　在夏瑜看来，“有一些公司可能从创业之初就非常明确说不涉及生产，不涉及未来的商业化，就做自己擅长的事，这也是一种很好的商业模式。但有一些企业，比如康方生物，其实我是没有为未来设限的，只要条件允许，符合公司发展战略，我们就推进。\n　　第一个条件，比如说我是有足够的人才和能力去把生产和商业化都做起来，这就需要一个更大的企业发展目标来推动了。另外，作为创始人，我也要有这个理想，我觉得这非常重要。因为越做到生产和商业化这个阶段，某种意义上说不可控性更强，勇气是必须要有的。”\n　　明知山有虎，偏向虎山行。这就是夏瑜的执着与坚韧。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：刘万里 SF014","news_type":1,"symbols_score_info":{"09926":1}},"isVote":1,"tweetType":1,"viewCount":3374,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":171666399,"gmtCreate":1626742493411,"gmtModify":1703764212411,"author":{"id":"3583528354923579","authorId":"3583528354923579","name":"锐哥来了","avatar":"https://static.tigerbbs.com/86eb4f1a6da7a549e0c096e4e1890a8e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583528354923579","authorIdStr":"3583528354923579"},"themes":[],"title":"","htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/171666399","repostId":"1159080706","repostType":4,"repost":{"id":"1159080706","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1626709038,"share":"https://ttm.financial/m/news/1159080706?lang=en_US&edition=fundamental","pubTime":"2021-07-19 23:37","market":"us","language":"zh","title":"[Movement] Recovering today's lost ground, Wei Xiaoli stopped falling and rebounded","url":"https://stock-news.laohu8.com/highlight/detail?id=1159080706","media":"老虎资讯综合","summary":"7月19日，理想汽车、蔚来、小鹏汽车止跌回升，收复今日失地。\n小鹏汽车此前公布旗下搭载量产车规级激光雷达的小鹏P5的预售价格，并宣布开启预售，小鹏P5新车预售价格16-23万元，共推出6个不同续航配置","content":"<p>On July 19,<a href=\"https://laohu8.com/S/LI\">Li Auto</a>、<a href=\"https://laohu8.com/S/NIO\">Nio</a>、<a href=\"https://laohu8.com/S/XPEV\">XPeng Motors</a>Stop falling and recover today's lost ground.</p><p>XPeng Automobile previously announced the pre-sale price of its XPeng P5 equipped with mass-produced car-grade lidar, and announced the opening of pre-sale. The pre-sale price of XPeng P5 new car is 160,000-230,000 yuan, and a total of six versions with different endurance configurations are available to choose from, with the maximum endurance reaching 600 kilometers under NEDC conditions.</p><p>At the same time, XPeng Automobile issued an announcement to issue 12,083,300 shares at an issue price of HK$165 per share on 19 July 2021 pursuant to the partial exercise of the over-allotment option.</p><p><img src=\"https://static.tigerbbs.com/f72a193fe4e67d7c18a4cbdff58c6864\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>[Movement] Recovering today's lost ground, Wei Xiaoli stopped falling and rebounded</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n[Movement] Recovering today's lost ground, Wei Xiaoli stopped falling and rebounded\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-07-19 23:37</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>On July 19,<a href=\"https://laohu8.com/S/LI\">Li Auto</a>、<a href=\"https://laohu8.com/S/NIO\">Nio</a>、<a href=\"https://laohu8.com/S/XPEV\">XPeng Motors</a>Stop falling and recover today's lost ground.</p><p>XPeng Automobile previously announced the pre-sale price of its XPeng P5 equipped with mass-produced car-grade lidar, and announced the opening of pre-sale. The pre-sale price of XPeng P5 new car is 160,000-230,000 yuan, and a total of six versions with different endurance configurations are available to choose from, with the maximum endurance reaching 600 kilometers under NEDC conditions.</p><p>At the same time, XPeng Automobile issued an announcement to issue 12,083,300 shares at an issue price of HK$165 per share on 19 July 2021 pursuant to the partial exercise of the over-allotment option.</p><p><img src=\"https://static.tigerbbs.com/f72a193fe4e67d7c18a4cbdff58c6864\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/1f36b37eb8e9efe8641c7be55a7da26d","relate_stocks":{"XPEV":"小鹏集团","09868":"小鹏集团-W","NIO":"蔚来","LI":"理想汽车"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1159080706","content_text":"7月19日，理想汽车、蔚来、小鹏汽车止跌回升，收复今日失地。\n小鹏汽车此前公布旗下搭载量产车规级激光雷达的小鹏P5的预售价格，并宣布开启预售，小鹏P5新车预售价格16-23万元，共推出6个不同续航配置的版本可供选择，NEDC工况下最高续航达到600公里。\n同时，小鹏汽车发布公告，于2021年7月19日因部分行使超额配股权而发行1208.33万股，每股发行价为165港元。","news_type":1,"symbols_score_info":{"XPEV":0.9,"LI":0.9,"09868":0.9,"NIO":0.9}},"isVote":1,"tweetType":1,"viewCount":3745,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}